NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 1of 98
CONFIDENTIAL
Study Title
A multicenter, multinational, randomized, doubl e-blind, pharm acokinetic and 
pharmacodynamic (PK/PD) dose-finding study of oral netupi tant administered 
concomitant ly with oral palonosetron in pediatric cancer patients for the prevent ion of 
nausea and vo miting associated with emetogenic chemotherapy.
Study Number NEPA -15-31
Protocol Version Final (v. 5.0)
Protocol Date 11 Feb 2019
Sponsor Helsinn Healt hcare SA
Via Pian Scairolo 9,
6912 Lugano/Pazzallo, Switzerland
IND Number: 73,493
CROPSI CRO AG 
Baarerstrasse 113a, 
6300 Zug, Switzerland
Confidential Information
The information contained in this document is confidential. Acceptance of this document constitutes
agreement by the recipient that no information contained herein will be published or disclosed without prior 
written authorizatio n from an official of Helsinn, except that this document may  be disclosed to appropriate 
Institutio nal Review Boards and Ethic s Committees or duly autho rized representatives of a Regulatory 
Authority under the condition that they are requested to keep it confidential.
The clinical trial will be conducted, and essential study documentation archived, in compliance with this 
protocol, applicable SOP’s and standards, which incorporate the requirements of the ICH Guideline for 
Good Clinical Practice.
Page 210 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 2of 98
CONFIDENTIAL
Docum ent H istory
With respect to final protocol versio n 3.0, dated 07 Feb 2017, the following changes were 
introduced in versio n4.0:
Inclusio n criterion #4 was updated to add imaging for initial diagnosis of nephrobastom a 
since European standard of care for nephroblastoma consists of adjuvant chemotherap y 
followed by nephrectomy  and histol ogy reports could be received several week s later, 
after the pati ent com pletes the study .
Inclusio n criteria were updated to include specific thresho lds for laboratory  parameters 
(ALT, AST, bilirubin, eGFR) as recommended by DSMB. Schwar tz equati on was 
provi ded as a recommended tool to calculate e GFR.
Exclusio n criteria were updated to include specific thresho lds for QTc parameters, as 
well as other safet y precauti ons related to pati ents’ concomitant conditions and laboratory 
abnorm alities,as recommended by  DSMB.
Clarificat ions related to the assessment of patients’ eligibilit y based on local laboratory 
param eters/autom ated interpretati on of cardiac param eters by ECG machine were added 
to the corresponding eligibilit y criteria sect ions and throughout the protocol as applicable.
Time window for palonosetron administration (interval after netupi tant administration) 
was added.
Administrative changes in the names of service provider companies and their 
representatives were made.
A misprint in footnote #3 of the Flow Chart on page 27 was corrected.
The d efinit ions of emet ic episode and regurgitation were added.
Clarificat ion on criteria for evaluating chem otherapy  schedule (single day vs. multiple 
days) was added.
Inform ation on emetogeni city of intravenous temozolomide was provi ded in Appendix 2 
following POGO Gui deline.
With respect to final protocol versio n 4.0, dated 06 Nov 2017, the following changes 
have been introduced in versio n 5.0:
Following a specific recommendat ion from FDA (US FDA Deferral Extensi onletter 
dated 15 Jan 2019), f or purpose sof facilitating enrollment in the study ,enrollment ofthe 
age cohorts 3 < 6 months and 1 < 3 months and birth < 1 month is allowed in parallel 
(instead of sequentially) ,keeping the ori ginal treatment dose escalati on scheme (i .e., first 
lowest doses are to be given in parallel  in all remaining age cohorts, then highest doses 
are to be given in parallel in all the remaining age cohorts ). This approach was also 
endorsed by DSMB members.
In Section 4.10.3 Other Prior and Conco mitant Medicat ions, an additional clarificati on 
was provided concerning the use of any drugs or substances known to be inhibitors of 
CYP3A4 and CYP2D6 enzymes (including any of the narrow therapeuti c range CYP3A4 
substrates), which are to be avoided within 1 week prior to Day 1 or during the overall 
Page 211 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 3of 98
CONFIDENTIAL
study  period (until  Visit 5 inclusive). It has also been clarified that the intake of drugs or 
substances known to be inducers of CYP3A4 enzymes wi thin 4 weeks pri or to the dosing 
day or use of  such medicat ions during the overall study peri od (until Visit 5 inclusive) is 
not permitted.
Consisten twith th e regulatory  recommendat ions set forth in docum ent entitled “Ethical 
considerations for clinical tri als on medicinal products conducted wi th minors , devel oped 
bythe European Commissio n expert group on clinical trials”,the volume of blood 
collected for the purposes of the clinical study in small children with body weight less 
than 5.4 kg shoul d be limit ed. Therefore ,Secti on 6.1 Pharm acokinetics Assessments was 
updated as follows:for small children less than 5.4 kg the volume of PK samples was 
adjusted from 2 mL to 1 mL and the total blood volume collected per patient has tobe 
approximately  3.0 mL. Moreover, each plasma sample hasto be immediately divided into 
2 aliquots in the pre-labeled polypropylene tubes: 1 aliquot ≥130 µL for the analysis of 
netupi tant and its metabo lites (M1, M2 and M3), and 1 aliquot of ≥250 µL for the 
analysis of palo nosetron –no back -up sam ples are to be obtained.
In Secti on 11. References, the reference s 14 and17of the Invest igator’s Brochure s for 
Palonosetron and Oral NEPA FDC respect ively wereupdate dto be with the latest 
versio ns.
Finally , in General  information some inform ation wascorrected (e.g., phone numbers , a 
new Sponsor’s Medical Expert for the study ) or updated (changed company the name of 
bioanalyt ical lab was changed). 
Page 212 of 323
Page 213 of 323NEPA-15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study Protocol ::HBLSINN 
Signature Page, Helsion Healthcare SA 
(Date) 
Study Coordinator: ~iA dO ~{ 9:) 
(Signature) (Date) 
Maria Elisa Borroni, MSc PharrnD 
Clinical Operations Manager, Clinical Research & Development 
Statistician: . ,.., ( 
..... CG\~.u.L_Wl~/o...__u. __ ?tf© ____ ~ ............. --- --M -n::.-B -2o19 
(Signature) (Date) 
Corinna Lanzarotti, MSc 
Statistics and Data Management Manager, Clinical Research & Development 
Clinical Pharmacologist: 
S?f:b0M.®)~J ./1~ -FF[:) -00/j 
(Signature) 
Alberto Bernareggi, MSc PharmD 
Director, Clinical Research & Development (Date) 
Drug Safety Specialist: -°1'-~-c/\-~ ......... < O\~R,__o_s_~-- A:1 --~ ~ 2-o ~3 
(Signature) (Date) 
Giorgia Rossi, MD 
Drug Safety Physician, Drug Safety 
Medical Writer: 
L A~N"'~ 
(Signature) (Date) 
Lara Ambrosetti, MSc 
Medical Writing Manager, Clinical Research & Development 
Page 4 of98 
CONFIDENTIAL 
Page 214 of 323NEPA -15-31 
Fina l (v. 5.0)/11 Feh 2019 
Signature Page, PSI CRO AG 
ProjectW== 
(Signatur e) 
Anastasia Eremceva , MSc 
Project Manager Projzz~ 
(Signature) 
Alexa nder Malitsky. MSc " 
Senior Group Leader Biostatistics Clinical Study Protocol 
(Date) 
l/.02. 2ol3 
(Date) 
Page 5 of98 
CONF IDENTIAL 
Page 215 of 323NEPA-15-31 .. 
Final (v. 5.0)/11 Feb 2019 Clinical Study Protocol •• ELSI 'N 
Signature Page, Certara Strategic Consulting 
Executive Director: 
M ~-======= (Signature) 
Henri Merdjan, PharmD 
Executive Director 13-(EB-£9 t 1 
(Date) 
Page 6 of98 
CONFIDENTIAL 
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 7of 98
CONFIDENTIAL
Signature Page, Principal Investigator 
Study Title
A multicenter, multinational, rando mized, doubl e-blind, pharmacokinet ic and 
pharmacodynamic (PK/PD) dose-finding study of oral netupi tant administered 
concomitant ly with oral palonosetron in pediatri c cancer patients for the prevent ion of 
nausea and vo miting associated with emetogenic chemotherapy.
Study Number NEPA -15-31
I have read and understood all pages of this clinical  trial protocol  and appendices and I 
agree that they contain all information requi red to conduct this trial. I agree to conduct 
the trial as outlined in the protocol  and to comply with all terms and cond itions set out 
therein. I confirm that I will conduct the trial in accordance with local regulat ions, ICH 
GCP gui delines and the provisi ons of  the Declarati on of Helsinki . I will direct, assist and 
oversee sub-Investi gator(s) and other relevant staff members under my control  and will 
ensure that all trial staff members have access to copies of this protocol  and to all 
inform ation relating to preclinical and prior clinical experience (e.g., Invest igator’s 
Brochure), ICH GCP guidelines, local regulat ions and the Declaration of Helsinki to 
enable them to work in accordance wit h the provisio ns of these documents. 
I agree that all docum entati on supplied to me by Helsinn and CRO concerning this trial 
will be kept in the strictest confidence.
_____________________ ___________________ __________________
(Signature) (Date)
Printed Name: 
Institution:
Page 216 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 8of 98
CONFIDENTIAL
TABLE OF CONTENTS
General Information .................................................................................................... 11
Study Synopsis ............................................................................................................. 14
Flow Chart ................................................................................................................... 27
LIST OF ABBREVIATIONS ...................................................................................... 29
1Introduc tion and Rationale .................................................................................. 33
1.1 Background Information ................................................................................. 33
1.2 Pre-clinical and Clinical Data of Palonosetron ............................................... 35
1.2.1 Pre-clinical Data ......................................................................................... 35
1.2.2 Summary of Phase 1 Clinical Data (Human pharmacokinetics) .............. 35
1.2.3 Clinical Data ............................................................................................... 38
1.3 Pre-clinical and Clinical Data of Netupitant ................................................... 40
1.3.1 Pre-clinical data .......................................................................................... 40
1.3.2 Summary of Phase 1 Clinical Data (Human pharmacokinetics) of 
Netupitant ................................................................................................... 40
1.3.3 Clinical Data ............................................................................................... 41
1.4 Study Rationale ................................................................................................ 42
2STUDY OBJECTIVES ......................................................................................... 44
2.1 Primary ............................................................................................................. 44
2.2 Seco ndary ......................................................................................................... 44
3STUDY PLAN ....................................................................................................... 45
3.1 Study Design ..................................................................................................... 45
3.2 Study Duration .................................................................................................46
3.3 Study Population .............................................................................................. 46
3.3.1 Number of Patients ..................................................................................... 47
3.3.2 Inclusion Criteria ....................................................................................... 47
3.3.3 Exclusion Cr iteria ...................................................................................... 48
4STUDY DRUG MANAGEMENT ........................................................................ 51
4.1 Description of Investigational Medicinal Products ......................................... 51
4.2 Treatment Groups ............................................................................................ 52
4.3 Dose and Administration ................................................................................. 52
4.4 Packaging and Shipment ................................................................................. 53
4.5 Storage .............................................................................................................. 54
4.6 Drug Depots ...................................................................................................... 54
4.7 Accountability .................................................................................................. 54
4.8 Randomization, Blinding and Assignment of Study Drug .............................. 54
4.8.1 Emergency Unblinding Procedure ............................................................ 55
4.9 Over -dosage ...................................................................................................... 56
4.10 Prior and Concomitant M edications ............................................................... 56
4.10.1 Prior and Concomitant Treatments for the Prevention of Nausea 
and Vomiting or with Potential Antiemetic Effect .................................... 56
4.10.2 Prior and Concomitant Cancer Chemotherapy and Radiotherapy ......... 58
4.10.3 Other Prior and Concomitant Medications ............................................... 58
Page 217 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 9of 98
CONFIDENTIAL
4.11 Rescue Medication ........................................................................................... 58
5STUDY CONDUCT .............................................................................................. 60
5.1 General Instructions ........................................................................................ 60
5.2 Study Procedures by Time Point ..................................................................... 60
5.2.1 Visit 1 (screening, Day -14 to -1 or Day -7 to -1 for patients aged < 
2 years) ........................................................................................................ 60
5.2.2 Visit 2 (Day 1) ............................................................................................. 61
5.2.3 Visit 3 (Day 2, 3, 4 and/or 5 depending on the PK sampling times) ......... 62
5.2.4 Visit 4 (final visit, Day 6, 7 or 8 depending on PK sampling times) ......... 62
5.2.5 Visit 5 (follow up visit, Day 14 [+3]) .......................................................... 63
5.3 Definition of Completion .................................................................................. 63
5.4 Premature Discontinuation .............................................................................. 63
6METHODS OF ASSESSMENT ........................................................................... 65
6.1 Pharmacokinetic Assessments ......................................................................... 65
6.1.1 PK Sam pling and Sample Handling .......................................................... 66
6.1.2 Analytical Procedures ................................................................................ 66
6.2 Efficacy Assessments ........................................................................................ 67
6.2.1 Primary Endpoint ...................................................................................... 67
6.2.2 Secondary Endp oints ................................................................................. 67
6.3 Safety Assessments ........................................................................................... 69
6.3.1 Physical Examination ................................................................................. 69
6.3.2 Vital Signs ................................................................................................... 69
6.3.3 12-lead ECG ............................................................................................... 69
6.3.4 Clinical Laboratory Tests .......................................................................... 70
7ADVERSE EVENTS ............................................................................................ 71
7.1 Method of Assessment ...................................................................................... 71
7.1.1 Definition of Adverse Events ...................................................................... 71
7.1.2 Classification of Adverse Events ................................................................ 72
7.1.3 Reporting of Adverse Events ..................................................................... 74
7.1.4 Reporting of Serious Adverse Events ........................................................ 74
7.1.5 Pregnancy Report ....................................................................................... 75
8STATISTICS ........................................................................................................ 76
8.1 Sample Size Determination .............................................................................. 76
8.2 Definition of Study Populations for Analysis .................................................. 77
8.3 Statistical Analysis ........................................................................................... 78
8.3.1 Missing Data ............................................................................................... 78
8.3.2 Covariates, Interactions and Subgroups ................................................... 78
8.3.3 Analysis of Demographics and Baseline Variables ................................... 78
8.3.4 Pharmacokinetic Analysis .......................................................................... 79
8.3.5 Efficacy Analyses ........................................................................................ 79
8.3.6 Pharmacokinetic/Pharmacodynamic Analysis .......................................... 80
8.3.7 Safety Analyses ........................................................................................... 80
8.4 Interim Analysis ............................................................................................... 80
9DATA SAFETY MONITORING BOARD .......................................................... 81
10ETHICAL AND REGULATORY CONSIDERATIONS ................................... 82
Page 218 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 10of 98
CONFIDENTIAL
10.1 Ethical Considerations ..................................................................................... 82
10.1.1 Laws and Regulations ................................................................................ 82
10.1.2 Patient’s Informati on Sheet, Informed Consent Form and Assent 
Form ........................................................................................................... 82
10.1.3 Protocol Amendments ................................................................................ 83
10.1.4 Protocol Deviations .................................................................................... 83
10.1.5 Data Coll ection ........................................................................................... 83
10.1.6 Monitoring and Quality Assurance ........................................................... 84
10.1.7 Study Documentation and Records Retention .......................................... 85
10.1.8 Confidentiality ............................................................................................ 85
10.1.9 Publication P olicy ....................................................................................... 85
10.1.10 Insurance .................................................................................................... 86
11REFERENCES ..................................................................................................... 87
12APPENDICES ...................................................................................................... 91
Appendix 1: Treatment Scheme .......................................................................... 92
Appendix 2: POGO Guideline for Classification of the Acute 
Emetoge nic Potential of Antineoplastic Medication in Pediatric 
Cancer Patients [35]* ....................................................................................... 93
Appendix 3: Eastern Cooperative Oncology Group Performance Status   
(ECOG PS) ....................................................................................................... 96
Appendix 4: CYP3A4 and CYP2D6 Inhibitors, Inducers and Substrates ......... 97
Appendix 5: Schwartz equation for determining estimated glomerular 
filtration rate (eGFR) ....................................................................................... 98
Page 219 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 11of 98
CONFIDENTIAL
GENERAL INFORMATION
Sponsor Helsinn Healt hcare SA
Via Pian Scai rolo 9
6912 Lugano/Pazzallo, Switzerland
Phone: +41 91 985 21 21
Fax: +41 91 985 21 22
CRO PSI CRO AG 
Baarerstrasse 113a, 
6300 Zug, Switzerland 
Phone: +41 (41) 228 1000
Fax: +41 (41) 228 1099
24h- Contact for Serious 
Adverse Events (SAEs)Toll-free 24 hours CRO Contact for Safety  Issues: 
SafetyDesk@psi -cro.com  
Country –specific toll-free fax lines will be provided in a 
separate document filed in the onsite site file.
Sponsor Drug Safety Officer Giorgia Rossi , MD
Phone: +41 91 985 19 35
Fax: +41 91 985 21 22
E-mail: Giorgia.Rossi@helsinn.com
(copi es to drug-safet y@helsinn.co m)
Sponsor Medical Expert Ruben Gi orgino, MD, PhD, MBA
Phone: +41 91 985 21 61
Fax: +41 91 985 21 22
E-mail: Ruben.Gi orgino @helsinn.co m  
Study Coordinator Helsinn:
Mari a Elisa Borroni , MSc Pharm D
Phone: +41 91 985 19 16
Fax: +41 91 985 21 22
E-mail: MariaElisa.Borroni@helsinn.co m
PSI CRO AG:
Anastasia Eremeeva, MSc
Phone: +7812 320 38 55
Fax: +7812 320 38 50
E-mail: Anastasia.Eremeeva@psi -cro.com
Page 220 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 12of 98
CONFIDENTIAL
Statistics Helsinn:
Corinna Lanzarotti, MSc
Phone: +41 91 985 19 84
Fax: +41 91 985 21 22
E-mail: corinna.lanzarotti@helsinn.co m
PSI CRO AG : 
Alexander Malitsky, MSc
Phone: +7812 320 38 55
Fax: +7812 320 38 50
E-mail: Alexander.Malitsky@psi -cro.com
Data Management Helsinn:
Riccardo Bezzo, MSc
Phone: +41 91 985 19 83
Fax: +41 91 985 21 22
E-mail: Riccardo.Bezzo@helsinn.co m
PSI CRO AG:
Ekaterina Osipova, MD, PhD
Phone: +7812 320 38 55
Fax: +7812 320 38 50
E-mail: Ekaterina.Osipova@psi -cro.com
Clinical Pharmacology Alberto Bernareggi, MSc PharmD
Phone: +41 91 985 19 34
Fax: +41 91 985 21 22
E-mail: Alberto.Bernareggi@helsinn.co m
Quality Assurance Helsinn:
Franco Faiella, MD
Phone: +41 91 985 21 64
Fax: +41 91 985 21 22
E-mail: Franco.Faiella@helsinn.co m
PSI CRO AG:
Olga Gol ubeva MD, PhD, MRQA
Phone: +7812 320 38 55
Fax: +7812 320 38 50
E-mail: Olga.Gol ubeva@psi -cro.com
Page 221 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 13of 98
CONFIDENTIAL
Central Laboratory ACM Global Central Laboratory  (ACM)
23 Hospi tal Fields Road ,York, UK YO10 4DZ
160 Elmgrove Park Rochester, New York 14624
Central ECG Reading ERT
1818 Market St., Suite 1000 Philadelphia, PA
EDC and IWRS System 
ProviderMedidata Solut ion Inc.
Metro Bl dg, 1 Butterwick, Hammersmit h, 
United Kingdom W6 8DL
Clinical Study Supplies
Packaging and LabelingCSM Europe SA (previously B&C Group)
Watson & Crick Hill
Rue Granbonpré 11, B -1435 Mont -Saint -Guibert, Belgium
Bioanalytical Lab for PK 
AssessmentArdena Biochemical Laboratory  B.V. (ABL)
W.A. Scho ltenstraat 7
9403 AJ Assen, The Netherlands
Population PK/PD Data 
Analysis CERTARA
37-39 avenue Ledru Rollin
75012 Paris
Henri Merdjan, PharmD
Execut ive Director
Direct Phone: +33 1 56 95 17 09
Mobile: +33 (0)6 25 67 74 19
Fax : +33 1 56 95 16 16
E-mail: henri .merdjan@certara.com
Page 222 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 14of 98
CONFIDENTIAL
STUDY SYNOPSIS
Study  Title A multicenter, multinational, randomized, double -blind, 
pharmacokinet ic and pharm acodynamic (PK/PD) dose-finding 
study of oral netupi tant administered conco mitantly with oral 
palonosetron in pediatri c cancer patients for the prevent ion of 
nausea and vo miting associated with emetogenic chemotherapy.
Study  Number NEPA -15-31
Sponsor Helsinn Healthcare SA, Via Pian Scairolo 9, 
6912 Lugano/Pazzallo, Switzerland
Countri es and Si tes A minimum of approximately 16 si tes in USA, Russia, Ukraine and 
Serbia; more sites and/or countries may  be added if necessary . 
Clinical Phase Phase 2
Indicat ion Chem otherapy -induced nausea and vo miting (CINV)
Study  Design This is a multicenter, multinational, randomized, doubl e-blind, 
stratified (by age class; by emetogeni city; by chem otherapy 
schedule), dose-finding study  involving two treatm ent groups 
receiving a single oral dose of netupi tant administered 
concomitant ly with a single oral  dose of 20 µg/kg oral palonosetron 
(up to a maximum o f 1.5 m g).
Netupi tant dose treatment groups: 
Treatment group 1: 1.33 m g/kg up to a maximum of 100 mg. For 
patients aged < 3 m onths, the netupi tant dose will be 0.8 mg/kg.
Treatment group 2: 4 mg/kg up to a maximum of 300 mg. For 
patients aged < 3 m onths, the netupi tant dose will be 2.4 mg/kg.
Pediatric popul ation will be split in the fo llowing age cl asses:
Birth to < 1 m onth
1 month to < 3 m onths
3 months to < 6 m onths
6 months to < 12 m onths
1 year to < 2 y ears
2 years to < 5 y ears
5 years to < 12 y ears
12 years to < 18 y ears.
At the beginning of the study , enrolment i s open only  to:
patients aged 1 year, who will be randomized to one of the two 
Page 223 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 15of 98
CONFIDENTIAL
netupi tant doses 
patients aged 6 months to < 12 months who will be treated with 
the netupi tant l ower dose (1.33 mg/kg).
At the beginning of the study  three patients aged 6 to < 12 months
will be first enrolled in the lower netupi tant dose group (1.33 
mg/kg). As soon as these first 3 patients have completed the study, 
without safet y and tolerabilit y concerns as assessed by Data Safet y 
Moni toring Board (DSMB), enrolment in the higher netupi tant dose 
group (4 mg/kg) of the same age class (6 to < 12 months) can start. 
As soon as 6 patients in the age class 6 to < 12 months (3 patients 
for each netupi tant dose group) have completed the study  without 
safet y and tolerabili ty concerns, decisi on by DSMB will have to be 
taken whether a) all remaining patients 6 to <12 months can be 
rando mized to one of the two netupitant treatment doses and start 
the assigned treatment, and b) the lower age class 3 to < 6 months
may start the treatment with the lower dose. 
The enrollment of the remaining cohorts will occur in parallel 
keeping the original treatment dose escalat ion scheme: 3 patients 
will be first treated wi th the lower netupi tant dose. As soon as these 
first 3 patients will have completed the study  and no safety and 
tolerabilit y concerns are shown, as assessed by the DSMB, 
enrolment in the higher dose group in the same age cla ss will  start .
Page 224 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 16of 98
CONFIDENTIAL
Study  Objectives Primary Object ive: 
To invest igate the PK/PD correl ation between netupi tant exposure 
and antiemetic efficacy after a single oral netupi tant administration, 
concomitant ly with oral palonosetron in pediatric cancer patients 
receiving moderately  emetogeni c chem otherapy (MEC) or highly 
emetogeni c chem otherapy (HEC) treatm ents. Efficacy parameter to 
be used in the correl ation is the proporti on of  patients with com plete 
response (CR, i.e., no emetic episodes and no rescue medicat ion) 
during the delayed phase (> 24-120 h after the start of 
chemotherapy on Day  1).
Secondary  Object ives: 
To assess the safet y and tolerabilit y after single oral administrati on 
of netupi tant given conco mitantly with a single oral administrati on 
of palonosetron.
To eval uate the PK profile of oral palonosetron at the fixed dose of 
20 µg/kg in pediatri c patients with the conco mitant administration 
of netupi tant.
Treatment Groups A total of 92 pediatric cancer patients will be enrolled to one of the 
two treatment groups (46 patients in each treatment group): 
Treatment group 1 –patients ≥ 3 months of age will receive a 
single oral netupi tant dose of 1.33 mg/kg (up to a maximum of 
100 mg for patients weighting 75 kg or more) concomitant ly 
with a  s ingle oral palonosetron dose of 20 µg/kg (up to a 
maximum of 1.5 mg for patients weighting 75 kg or more). For 
patients < 3 m onths of age the netupitant dose will be 0.8 mg/kg.
Treatment group 2 –patients ≥ 3 months of age will receive a 
single oral netupi tant dose of 4 mg/kg (up to a maximum of 
300mg for patients weighting 75 kg or more) concomitant ly 
with a  s ingle oral palonosetron dose of 20 µg/kg (up to a 
maximum of 1.5 mg for patients weighting 75 kg or more).For 
patients < 3 m onths of age the netupitant dose will be 2.4 mg/kg.
Dosage and 
Administrati onIn order to allow the administrati on of the study  drug according to 
the two netupitant treatm ent doses, three Invest igational Medicinal 
Products (IMPs) will be used in the study :
IMP 1 : Oral  liquid form ulation of  netupi tant (100 mg/7 mL) suitable 
for use in all pediatri c age classes. Netupi tant will be administered 
based on the body  weight as a single oral dose 1 h (± 10 minutes)
prior to start of emetogenic chemotherapy  (HEC or MEC) on Day  1. 
IMP 2 : Oral  liquid form ulation of  netupi tant (300 mg/7 mL) suitable 
for use in all pediatri c age classes. Netupi tant will be administered 
Page 225 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 17of 98
CONFIDENTIAL
based on the body  weight as a single oral dose 1 h (± 10 minutes) 
prior to start of emetogenic chemotherapy  (HEC or MEC) on Day  1. 
IMP 3: Palonosetron will be administered orally using the 
0.75 mg/5 mL solution for IV use. Palonosetron will be 
administered based on the body  weight, imme diately (within 5 
minutes) after netupitant, i.e., 1 h (± 10 minutes) prior to start of 
emetogeni c chem otherapy (HEC or MEC) on Day  1. 
Target Study  
Popul ationMale and female pediatric cancer patients from birth up to <18 
years, scheduled to receive HEC or MEC to be admin istered as 
single day chemotherapy  on Day 1 only  or for multiple days.
Number of Patients A total of 92 pediatri c patients will be enrolled to one of the two 
treatm ent groups (i.e., 46 in each treatment group). 
For each age class included in the stratification, the relevant planned 
number of patients to be enrolled is provided belo w.
-Birth to < 1 m onth: 12 pati ents
-1 to < 3 months: 12 patients
-3 to < 6 months: 8 patients
-6 to < 12 months: 8 patients
-1 to < 2 y ears: 8 patients
-2 to < 5 y ears: 12 pa tients
-5 to < 12 y ears: 16 patients
-12 to < 18 y ears: 16 patients
Stratificat ion The study  is stratified by:
- Age class:
•Birth to < 1 m onth 
•1 to < 3 months 
•3 to < 6 months 
•6 to < 12 months 
•1 to < 2 y ears
•2 to < 5 y ears 
•5 to < 12 y ears 
•12 to < 18 years 
- Emetogenicit y: 
•HEC
• MEC
- Chem otherapy  schedule: 
•HEC/MEC on Day  1 only
•HEC/MEC on mult iple days
Note that the Emetogeni city and Chem otherapy schedule strata do 
not apply for patients < 1 year of age (i.e., all age classes < 12 
Page 226 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 18of 98
CONFIDENTIAL
months).
Chem otherapy  
RegimensAny chem otherapy regimen of moderate or high emetogeni city to 
be administered as single day chem otherapy on Day 1 only or on 
multiple days can be used in this study . For consistency of 
interpretation, “mult iple days” schedule woul d include regimens 
with additional HEC/MEC given between Day 1 and Day 6 (within 
120 hours from the start of first HEC/MEC administration on Day 
1).Any low emetogeni c chem otherapy (LEC) agent or minimally 
emetogeni c chem otherapy  agent given, as part of the 
aforem entioned chem otherapy regimens using HEC or MEC, is 
allowed at any  time.
Rescue Medicat ionRescue medication is defined as any medicat ion taken to alleviate 
nausea or vomi ting (i .e., wi th indicati on nausea or vomi ting) during 
the period fro m start o f HEC or MEC to 120 h later.
The choice of rescue medicat ion will be at the discret ion of the 
Invest igator. Use of palonosetron or netupitant other than study 
drugs administrati on is not permi tted. Use of metocl opramide is not 
allowed. 
Inclusio n Cri teria The fo llowing inclusion criteria must be checked prior to inclusio n:
1.Signed wri tten informed consent by parent(s)/l egal guardi ans of 
the pediatric patient in compliance with the local laws and 
regul ations. In addi tion signed children’s assent form  according 
to local requi rements.
2.Male or f emale in-or out -patient from birth to < 18 years at the 
time of rando mizat ion.
3.Patient wei ght at least 3.3 kg.
4.Naïve or non-naïve patient with histol ogically , and/or 
cytologically (or imaging in the case of brain tumors or 
nephroblastoma ) confirmed m alignant di sease.
5.Scheduled and eligible to receive at least one moderately  or 
highly emetogenic chemotherapeut ic agent on Day 1 only or for 
multiple days.
6.For patient aged ≥ 10 years: Eastern Cooperative Onco logy 
Group Performance Status (ECOG PS) ≤ 2.
7.Adequate hepat ic funct ion defined as serum  ALT and AST ≤ 
2.5 ULN, and total bilirubin ≤ 1.5 ULN.
8.Adequate renal function defined as est imated glomerular 
filtrat ion rate (eGFR) ≥ 70 ml/min/1.73m2(≥ 50 ml/min/1.73m2
Page 227 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 19of 98
CONFIDENTIAL
for children < 3 months old). The eGFR shoul d be calculated 
using the modified Schwartz equation.
9.For patient with known history  or predisposit ion to cardiac 
abnorm alities: in the Investi gator’s opinio n the 
history /predisposi tion shoul d not jeopardize patient’s safet y 
during the study .
10.If the pat ient is female, she shall: a) not have attained menarche 
yet or b) have attained menarche and have a negat ive pregnancy 
test at the screening visit and at Day  1. 
11.Male or female fertile patient using reliable contraceptiv e 
measures (such measures, for patient and sexual partner, 
include: implants, injectables, combined oral contraceptives, 
intrauterine devices, vasectomized/sterilized partner, use of a 
doubl e-barrier method or sexual abstinence). The patient and 
his/her parent(s)/legal guardi ans must be counseled on the 
importance of avo iding pregnancy before or during the study.
All inclusion criteria will be checked at screening visit (Visi t 1). 
Inclusio n criteria #3, 5, 10 will be re -checked at Day 1 (Visit 2).
Local  laboratory  results from an appropri ately certified local 
laboratory  coul d be used at the discreti on of  Investigator to eval uate 
patients’ eligibilit y.
Exclusio n Cri teria The fo llowing exclusio n criteria must be checked pri or to inclusio n:
1.The patient and/or parents/caregivers are expected by the 
Invest igator to be non -compliant wi th the study  procedures. 
2.Patient has received or is scheduled to receive total body 
irradi ation, total  nodal i rradiat ion, upper abdom en radi otherapy , 
half or uppe r body irradiation, radiotherapy  of the cranium, 
craniospinal regions, head and neck, lower thorax region or the 
pelvis within 1 week prior to study entry  (Day 1) or within 
120h after start of chemotherapy administration on Day 1. 
3.Known history  of allerg y to any component or other 
contraindicat ions to any  NK 1or 5-HT 3receptor antagonists.
4.Active infection.
5.Any illness or condition that, in the opini on of the Invest igator, 
may pose unwarranted risks in administering the investigational 
product to the patient .
6.Patient suffering from ongoing vomit ing from any organic 
etiology (including patients with history  of gastri c outlet 
obstructi on or intestinal obstructi on due to adhesio ns or 
Page 228 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 20of 98
CONFIDENTIAL
volvulus, patients with a symptomatic CNS tumor causing 
nausea and/or vo miting) or patient with hydrocephalus. 
7.Patient who experienced any vomiting, retching, or nausea 
within 24 h prior to the administration of the study  drug (note: 
funct ional vomiting for infants, which is norm ally seen during 
the first 3 months of life, is not to be considered as vomit ing).
8.Patient who received any drug with potenti al anti-emetic effect 
within 24 h prior to the start of reference chem otherapy , 
including but not limited to:
-NK 1-receptor antagonists (e.g., aprepitant or any other new 
drug of this cl ass); 
- 5 -HT 3receptor antagonists (e.g., ondansetron, granisetron, 
dolasetron, tropi setron, ram osetron);
-Benzamides (e.g., metoclopramide, alizapride);
-Phenothi azines (e.g., prochlorperazine, promethazine, 
perphenazine, fluphenazine, chlorprom azine , 
theithylperazine);
-Benzodi azepines initiated 48 h prior to study  drug 
administration or expected to be received within 120 h 
following init iation of chem otherapy , except for single doses 
of midazo lam, tem azepam  or tri azolam;
-Buty rophenones (e.g., droperi dol, haloperi dol);
-Anticholinergics (e.g., scopolamine, with the excepti on of 
inhaled anticholinergics for respi ratory  disorders e.g., 
ipratropium bromide); 
-Antihistamines (e.g., diphenhydramine, cyclizine, 
hydroxyzine, chlorphenhy ramine, dimenhydrinate, 
meclizine);
-Dom peridone; 
-Mirtazapine; 
-Olanzapine; 
-Prescribed cannabino ides (e.g., tetrahy drocannabino l, 
nabilo ne);
-Over the Counter (OTC) antiemet ics, OTC cold or OTC 
allergy  medicati ons;
-Herbal preparations containing ephedra or ginger.
9.Patient who received palonosetron within 1 week prior to 
Page 229 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 21of 98
CONFIDENTIAL
administration of study  drug. 
10.Patient who has been started on systemic corticosteroi d therapy 
within 72 h prior to study  drug administration or is planned to 
receive a corticosteroid as part of the chemotherapy re gimen.
Except ions:
-Patient who is receiving chronic (> 72 h), daily steroi d 
therapy  can be enrolled provi ded the steroi d dose is not 
>0.14 mg/kg (up to 10 mg) of predniso ne daily  or 
equivalent.
-For supportive care, patient is permi tted to receive a single
dose of corticosteroi d within the 72 h prior to study drug 
administration (but not < 12 h prior to study drug 
administration) provi ded it is less than the equivalent of 
20mg o f prednisone.
11.Patient aged < 6 years who received any invest igational drug 
(defined as a medicat ion with no market ing authori zation 
granted for any age class and any indicat ion) within 90 days 
prior to Day 1, or patient aged 6 years who received any 
investigat ional drug within 30 days prior to Day 1  o r is 
expected to receive invest igational drugs prior to study 
completion.
12.Intake of al coho l, food or beverages (e.g., grapefrui t, cranberry ,
pomegranate and aloe vera juices, German chamomile) known 
to interfere with either CYP3A4 or CYP2D6 metabolic 
enzymes within 1 week prior to Day 1and during the overall 
study  period.
13.Use of any drugs or substances known to be strong or m oderate 
inhibitors of CYP3A4 and CYP2D6 enzymes within 1 week 
prior to Day 1 or planned to be used during the overall study  
period.
14.Use of any drugs or substances known to be CYP3A4 
substrates wi th narrow therapeutic range wi thin 1 week pri or to 
Day 1, or pl anned to be used during the overall study  period.
15.Use of any drugs or substances known to be inducers of 
CYP3A4 enzymes within 4 weeks prior to Day  1 or planned to 
be used during the overall study  period.
16.Lactating female pat ient. 
17.Patient wi th clinically  relevant Grade 3 or 4 non-hematological 
abnorm al laboratory  values.
Page 230 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 22of 98
CONFIDENTIAL
20.Enrolment in a previ ous study  with netupi tant (ei ther alone or in 
combinat ion with palonosetro n).
21.Marked baseline prolongat ion of QTc interval [QTcB orQTcF > 
460 msec] at screening.
NOTE: Exclusion criteria ## 18 and 19 were skipped intentionally 
to maintain consistency in exclusi on criteria numbering between 
protocol  amendments.
All exclusio n criteria will be checked at screening visit (Visi t 1). 
Exclusio n criteria #2, 4, 7, 8, 9, 10, 11, 12, 13, 14, 15, 17, 21 will be 
re-checked at Day 1 (Visi t 2). In case of ERT central  ECG report 
pending, the assessment of compliance with exclusi on criterion#21 
could be made based on automatic interpretati on of QTcB and 
QTcF results by ECG machine at the discretion of Invest igator.
All eligible patientsmust be approved for randomizat ion by 
authori zed Medical Monitor .
Study  Durati on The planned durat ion of the study  for each pediatri c patient is a 
maximum of 31 days, which includes screening up to 14 days 
before randomizat ion (up to 7 days for pati ents aged < 2 years), day 
of enrolment/rando mizat ion, administration of study drugs and 
chemotherapy (Study  Day 1), and the PK visit (Study  Days 2 to 5). 
The final visit will be 6 to 8 days after study  drug administration, 
and a follow up visit/telephone contact will be performed between 
14 and 17 day s after study  drug administrati on. 
Study  Endpo ints Primary Endpo int:
PK/PD rel ationship between netupitant exposure (AUC, C max) and 
antiemetic efficacy in the delayed phase after a single oral 
netupi tant administration, concomitant ly wit h oral  palonosetron, in 
pediatric cancer patients receiving HEC or MEC treatme nts. 
Efficacy parameter to be used in the correlat ion is the proportion of 
patients wi th com plete response (CR, i .e., no emetic episodes and 
no rescue m edicat ion) during the delayed phase (> 24 -120 h after 
the start of chemotherapy  on Day  1). 
Secondary  Endpoints:
-Pharmacokinet ic (PK) endpo ints: 
•AUC, Cmax, tmaxand t1/2of netupi tant, netupitant metabo lites 
M1, M2, M3, and palonosetron.
-Pharmacodynamic (PD) endpoints: 
•proporti on of  patients with complete response (CR, i.e., no 
emetic episodes and no rescue m edicat ion) during the del ayed 
(> 24 -120 h), acute (0 -24 h) and overall phases (0 -120 h) after 
Page 231 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 23of 98
CONFIDENTIAL
start of chemotherapy administration on Day  1.
•proporti on of patients with no emetic episodes during the 
delayed (> 24-120 h), acute ( 0-24 h) and overall phases (0-120 
h) after start of chemotherapy administration on Day 1.
•proporti on of patients with no rescue medication during the 
delayed (>24-120 h), acute (0-24 h) and overall  phases 
(0-120 h) after start of chemotherapy administrati on on 
Day 1. 
Assessment of the 
Pharmacokinet ic 
ProfileThe PK profiles of netupi tant, its active metabolites M1, M2, M3, 
and palonosetron will be evaluated in pediatric cancer patients 
according to a sparse sampling schedule and a popul ation PK 
approach. 
A single blood sam ple will  be collected from each pati ent in each of 
the following time windows:
Pediatric patients ≥ 5 years: from 2 to 8 h, from 24 to 48 h, 
from 72 to 96 h, and from 120 to 168 h after netupi tant 
administration .
Pediatric patients < 5 years: from 2 to 8 h, from 24 to 48 h, 
and fro m 120 to 168 h after netupi tant administrati on.
The nominal number of plasma samples collected from all patients 
after each of the two treatm ents will be 154. The expected total 
number of pl asma samples collected after the two treatm ents will be 
308. 
The volume of each blood sample will be 2.0 mL. For patient with 
body  weight <5.4 kg, the volumeof each blood sample will be 1.0 
mL.
Data modelling will be based on a previous populati on PK study  in 
adults receiving oral NEP A (study  NETU -10-02). 
If the same structural  models apply to the pediatric popul ation, the 
typical  values (TV) of the following structural  model parameters 
will be assessed for netupitant and palonosetron: 
-Ka: absorpti on rate constant for netupitant or formation rate 
constant for netupitant metabo lites
- t lag: lag time
-Vi/F: apparent volume of compartment i, i.e., central and 
peripheral  com partment(s), for extravascular administration
-CL/F: apparent systemic clearance for extravascular 
administration
-Q/F: inter -compartmental clea rance
F is the absol ute oral bioavailabilit y for the parent compounds 
netupi tant and pal onosetron. 
Different structural models coul d also be explored f or netupi tant, i ts 
Page 232 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 24of 98
CONFIDENTIAL
metabo lites, and palonosetron according to the findings of the 
present PK/PD study  inpediatri c patients after oral administrati on 
of netupi tant and palonosetron. The final model parameters will 
reflect the model structure and include possible continuous or 
categori cal covariates that significant ly correl ate with PK 
param eters and explain inter-subject variabilit y. 
Individual model-predi cted PK param eter values will be estimated 
from the final popul ation pharmacokinet ic models, based on mean 
popul ation parameter values (typical values, TVs) and on the 
individual random  effect (ηi). From  final model parameters, 
individual plasma concentrati on-time profiles will be simulated and 
secondary  PK param eters such as Cmax, tmax, AUC and t1/2estimated 
by non-compartmental methods.
Efficacy 
AssessmentsEfficacy assessments will be collected through a paper diary , which 
will be used to record emetic episodes and use of rescue medicat ion. 
Patients, parent’s guardi ans or caregivers shoul d complete the 
diaries.
Safety 
AssessmentsSafety assessments will consist of physical examinat ion (PE) and 
clinical laboratory  tests (serum  chemistry , hematol ogy, urinalysis): 
these assessments will be performed at screening and at final visit. 
Moreover, vital signs measurements (pulse rate, systolic and
diastolic blood pressure) and 12-lead ECGs (single recordings) will 
be obtained at screening, on Day 1 at 4-6 h after study  drug 
administration, and at final visit. 
Adverse events (AEs) will be monitored throughout the study .
During the conduct of the study, a Data Safet y Moni toring Board 
(DSMB) will review safety  data,as foreseen by the study  design 
and at periodical intervals.
PK/PD Correlat ionPK/PD relationships between predicted individual exposure metrics 
(Cmaxand AUC) of netupi tant at different dose levels versus 
efficacy (CR delayed) will be invest igated via graphical expl oratory  
analyses. In addition, a logistic regressio n analysis will be used to 
link the exposure metrics to categori cal response (CR delayed ). The 
dose-exposure relationship and the PK/PD correlat ion (exposure -
response rel ationship) for netupi tant in pediatri c cancer pati ents will 
support the dose select ion for a subsequent Phase 3 study . 
Pharmacokinet ic 
AnalysesExploratory  analyses will beapplied to evaluate in the pediatric 
popul ation the PK  characteri stics of netupi tant (and its metabo lites) 
and palonosetron after concomitant administration. The initial 
popul ation PK models (base models) will be developed by 
comparing structural  models and random error models based on 
Page 233 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 25of 98
CONFIDENTIAL
param eters such as the objective function values, the log-likelihood 
values, the Akaike’s and the Bayesian’s Information Criteria (AIC 
and BIC), the residual errors, the random distributio n in condi tional 
weighted residual plots, the graphical correl ation between the 
observed versus predicted concentration values.
The final popul ation PK models will include possible additional 
fixed effects represented by relevant covari ates that will prove to 
correl ate wi th one or m ore popul ation PK parameters and contribute 
to significantly explain and minimize the inter -subject variabilit y. 
The final model will be qualified via a visual predictive check.
Inter -subject / inter-occasi on variabilit y (level 1 rando m-effect) and 
observat ion-level rando m error (level 2 rando m effect) will also be 
modeled.
Individual model-predi cted PK param eter values will be estimated 
from the final popul ation pharmacokinet ic models, based on mean 
popul ation parameter values (typical values, TVs) and on the 
individual random  effect (ηi). From  final model  parameters, 
individual plasma concentrati on-time profiles will be simulated and 
secondary  PK param eters such as Cmax, tmax, AU C and t1/2estimated 
by non-compartmental methods.
Mean and coefficient of variation (CV) of the pharmacokinet ic 
param eters will  be calculated fro m the individual predict ions.
The effect of continuous and categori cal covariates on the PK 
param eter variabil ity will be evaluated by step-wise forward 
addition and backward eliminat ion procedures. Continuous 
covari ates will include at least age, BW, albumin, total bilirubin, 
creatinine, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), alkaline phosphatase (ALP). Categorical 
covari ates will include at least gender, HEC/MEC, chemotherap y 
schedule, rescue medicat ion (yes/no), concomitant medicat ions.
Data from previous popul ation PK study  NETU -10-02 in adult 
cancer patients receiving oral NEPA FDC administration (300m g 
netupi tant/0.5m g palonosetron) will be used as prior informat ion 
and included in the analysis. 
Page 234 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 26of 98
CONFIDENTIAL
Efficacy Analysis All resul ts will be interpreted in a descri ptive manner, since the 
study  is not powered to compare the treatm ent group s for the 
efficacy  assessments.
For each phase (delayed, acute, and overall), numbers and 
percentages (including 95% CI) of  patients with complete response, 
with no emetic episodes and no rescue medi cation will be 
summarized by treatm ent. The difference inresponse rate between 
the two groups and relevant 95% CI will be provided as well.
Efficacy analysis will be presented for the overall populat ion and by 
strata.
Safety Analysis All AEs will be listed by SOC, described and summarized by 
frequency tables. Summaries will be made by treatm ent arm with 
respect to th e percentage of patients having at least one occurrence 
of that event during the study  and the total  number of events.
For safet y analysis, the laboratory  data will be analyzed and 
described as follows: listings (including flag for values outsi de the 
norm al range), count (number and percentage) of value below, 
within and above norm al range, descriptive statist ics for change 
from baseline values. Shift tables with respect to norm al range 
(Low/Norm al/High) will be presented. ECG data will be 
summarized highlighting differences from baseline for quantitative 
variables and frequencies o f treatm ent em ergent abnorm alities. Vi tal 
signs will be summari zed using descript ive statisti cs for observed 
values and c hange fro m baseline, in addit ion to being listed. 
Safety analysis will be presented for the overall safet y popul ation 
and by  strata.
Page 235 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 27of 98
CONFIDENTIAL
FLOW CHART
Visit V1 V2 V3 V4 V514
Timepoint (Day) -14 to -1;
-7 to -1 
for < 2 years1 2, 3, 4 
and/or 56, 7 or 8 14 [+3]
Assessments Screening Randomization
/ TreatmentPK Visit Final Visit Follow up
Informed Consent/Assent X
Inclusion/Exclusion Criteria X X10
Demography, medical and surgical 
history (including current cancer 
history, naivety to chemotherapy)X
History of nausea and vomiting in 
previous chemotherapy1 X
ECOG status2X
Hematology, Serum chemistry, 
Urinalysis3 X X
Pregnancy test (urine)4X X
Physical examination X X
Vital signs X X11, 12X11
Height /Length X
Weight X X
12-lead ECG5X X12, 13X13
Randomization / Treatment 
assignmentX
Study  drugs administration6X
Record efficacy parameters Recording up to 120h
Patient Diary Instruction Filled in up to 120h
Collection of Patient Diary7X
Prior and concomitant medication 
recordingX X X X X
Adverse event monitoring8X X X X X
PK sampling9X X X
1 Only if applicable (for non -naïve patients).
2 ECOG status will be assessed for patients aged ≥ 10 years.
3 Whole blood, serum and urine samples will be sent to a central laboratory. Urine sample will be obtained only if the 
patient is capable of providing a urine sample. At the final visit (Visit 4) only, serum sample will also be used for 
pregnancy test.
4 For female patients having reached menarche only. If screening is performed on Day -1, it is not necessary  to repeat the 
test on Day 1.
5 12- lead ECG (single recording) will be evaluated in a central reading facility.
Page 236 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 28of 98
CONFIDENTIAL
6 Study  drugs will be administered as follows: 
-Netupitant will be administered based on the body weight as a single oral dose 1 h (± 10 minutes) prior to the start 
of emetogenic (HEC or MEC) chemotherapy on Day 1.
-Oral palonosetron will be administered based on weight immediately  (within 5 minutes) after netupitant, i.e. , 1 h 
(± 10 minutes) prior to start of emetogenic (HEC or MEC) chemotherapy on Day 1.
-Any LEC or minimally emetogenic agent given, as part of the aforementioned chemotherapy regimens using HEC 
or MEC, is allowed at any time during the study and does not have any impact on the time of study  drugs 
administration.
7 The patient will be instructed to bring the diary back to the site at each visit so that the Investigator is able to ensure i t 
has been completed in a timely and appropriate manner .
8 Starting at the s creening visit, immediately after informed consent/assent, up to the follow up visit/telephone contact.
9 A single blood sample will be collected from each patient in each of the following time windows: 
-Pediatric patients ≥ 5 y ears: from 2 to 8 h, from 24 to 48 h, from 72 to 96 h, and from 120 to 168 h after netupitant 
administration. 
-Pediatric patients < 5 years: from 2 to 8 h, from 24 to 48 h, and from 120 to 168 h after netupitant administration.
10 On Day 1, inclusion criteria #3, 5, 10 and Exclusion criteria #2, 4, 7, 8, 9, 10, 11, 12, 13, 14, 15, 17, 21 should be re -
checked prior to randomization/enrollment (local laboratory results from an appropriately certified local laboratory 
could be used at the discretion of Investigator to evaluate patients’ eligibility ; in case of ERT central ECG report 
pending, the assessment of compliance with exclusion criterion #21 could be made based on automatic interpretation of 
QTcB and QTcF results by ECG machine at th e discretion of Investigator ).
11 Vital signs to be measured before PK sampling or at least 30 minutes after PK sampling.
12 Vital signs and 12 -lead ECGs (single recording) will be obtained at 4 -6 h after study drugs administration.
13 12- lead ECGs (single recordin g) to be obtained before PK sampling or at least 30 minutes after PK sampling.
14 Follow up Visit / Telephone Contact (14 [+3] days after drug administration).
Page 237 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 29of 98
CONFIDENTIAL
LIST OF ABBREVIATIONS
5-HT 3 5-hydroxy tryptamine
ADE Age-dependent exponent
ADL Activities o f Daily Living
ADME Absorpti on, di stributi on, metabolism , excreti on
AE Ad verse Event
AIC Akaike’s Informat ion Cri teria
ALP Alkaline phosphatase
ALT Alanine aminotransferase
ANOVA Analysis of variance
API Active Pharmaceut ical Ingredients
AST Aspartate aminotransferase
AUC Area Under the Plasma Concentration- Time Curve
BIC Bayesian’s Informat ion Cri teria
BW Body  weight
CDC Centers for Disease Control and Prevent ion 
CI Confidence Interval
CL Systemic (or total ) Clearance
CK Creatine kinase
CL/F Apparent sy stemic clearance for extravascular administration
CL R Renal clearance
CINV Chem otherapy -Induced Nausea and Vo miting
Cmax Maximum Plasma Concentration
CR Com plete response
CRO Contract Research Organization
CSR Clinical Study  Report
CTCAE Commo n Termino logy Criteria f or Adverse Events
CYP Cytochrom e P450
CV Coefficient of variat ion
DCF Data Cl arificat ion Form
DSMB Data Safet y Moni toring Board
EC Ethics Co mmit tee
Page 238 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 30of 98
CONFIDENTIAL
ECG Electrocardiogram
ECOG PS Eastern Cooperative Oncology Group Perform ance Status
eCRF Electronic Case Report Form
EDC Electronic Data Capture
EEA
eGFR
ESMOEuropean Economic Area
Estimated Glo merular Filtration Rate
European Societ y for Medi cal Onco logy
EU European Unio n
F Oral Bioavailabili ty
FAS Full Analysis Set
FDA Food and Drug Administration
FDC Fixed -dose combinat ion
GCP Good Clinical Pract ice
h Hour
HEC Highly Emetogeni c Chem otherapy
IB Invest igator’s Brochure
ICH International Council for Harmonisat ion
IEC Independent Ethics Committee
IND Invest igational New Drug
IMP Invest igational Medicinal Product
IRB Institutional Review Board
IV Intravenous
IWRS Interactive Web Response Sy stem
Ka Absorpti on Rate Constant
K2-EDTA Di-potassi um Ethylenediaminetetraacetic acid
LC-MS/MS Liquid chrom atography  with tandem  mass spectrometry
LEC Low Em etogeni c Chem otherapy
LLOQ Lower limits of quantificat ion
MASCC Multinational Associ ation of Supportive Care in Cancer
M1,2,3 Metabo lites 1,2,3
MEC Moderately Emetogenic Chemotherapy
Page 239 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 31of 98
CONFIDENTIAL
NEPA Netupi tant pl us Pal onosetron
NCCN National Com prehensive Cancer Network
NK 1 Neurokinin -1
NEPA FDC Oral Netupi tant pl us Pal onosetron Fixed Dose Combinat ion
NETU Netupi tant
ηi Individual rando m effect
OECD Organisat ion for Economic Co -operati on and Dev elopment
OTC Over The Counter
PALO Palonosetron
PD Pharmacodynamic
PE Physical Examinat ion
PK Pharmacokinet ic
POGO Pediatric Onco logy Group of Ontari o
PONV Post-operative nausea and vo miting
Q/F Inter -compart mental clearance
QTc QT Interval  Corrected
QTcB QT Interval  Corrected by  Heart Rate Using the Bazett formula
QTcF QT Interval  Corrected by  Heart Rate Using the Fridericiaformula
RBC Red Bl ood Cells
SAE Serious Adverse Event
SAP Statistical Analysis Plan
SD Standard Deviation
SDV Source Data Verificat ion
SE Standard Error
SOC System  Organ Class
SOP Standard Operating Procedure
SUSAR Suspected Unexpected Serious Adverse React ions 
TBD To be defined
TEAE Treatment -Emergent Adverse Event
tlag Lag Time
tmax Time to reach maximum (peak) plasma concentrati on following drug 
administration
Page 240 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 32of 98
CONFIDENTIAL
t1/2 Terminal half -life
TV Typical  values
ULN
US/USAUpper limit of normal
United States/United States of America
Vd Apparent Vol ume of Distribut ion
Vi/F Apparent volume of compartm ent i, i.e., central  and peripheral 
compartment(s), for extravascular administration
WBC White Blood Cells
Page 241 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 33of 98
CONFIDENTIAL
1INTRODUCTION AND RAT IONALE
1.1 Background Information
Chem otherapy -induced nausea and vomiting (CINV) is a common and distressing side-
effect of cancer chem otherapy regimens in adults, but is also a major probl em in the 
treatm ent of childhood malignancies. [1, 2, 3] 
Adult patients in whom CINV is left unco ntrolled, experience a severe deteri oration in 
their quali ty of life and may experience malnourishment, anxiet y, and depressi on. Fear of 
CINV is sufficient for many patients to postpone or even refuse potenti ally life-saving 
treatm ent. [3, 4, 5, 6] However, antiemet ics can improve qualit y of life, increase 
treatm ent com pliance and effectiveness, and theref ore improve patient outcome. [7] 
Antiemetics counter CINV by antagonising the 5-hydroxy tryptamine subty pe 3 (5-HT 3) 
receptor or the neurokinin -1 (NK 1) receptor. Currently, in adult patients undergo ing 
highly emetogenic chem otherapy, the administrati on of a 5-HT 3receptor antagonist 
alongsi de with a NK1receptor antagonist, in association with dexamethasone, is 
recommended for the treatment of acute CINV. [8, 9] 
For pati ents undergoing a moderately emetogenic chemotherapy regimen, not including a 
combinat ion of anthracycline plus cyclophosphamide, the 5-HT 3receptor antagonist 
palonosetron hydrochloride (Alo xi®) plus dexamethasone is recommended. [9]
In pediatri c patients, Multinational Associ ation of Supporti ve Care in Cancer (MASCC) 
and European Society for Medical Onco logy (ESMO) guidelines recommend 
prophylact ic antiemetic therapy comprising a 5-HT 3receptor antagonist and 
dexamethasone to prevent acute CINV in pat ients scheduled to receive HEC or MEC. For 
prevent ion of delayed CINV, no appropriate studies in children are so far available and 
therefore no formal recommendat ion is possible. According to MASCC/ESMO 
guidelines, however, many panelists suggest that children shoul d be treated in a manner 
similar to that of adults receiving chem otherapy  of this risk, and that doses shoul d be 
adjusted appropriately for children. [2, 9]The Pediatric Onco logy Group of Ontario 
(POGO) Guideline for the Prevent ion of Acute Nausea and Vomiting due to 
Antineoplastic Medicati on in Pediatri c Cancer Patients recommend that children 
scheduled to receive highly  emetogenic chem otherapy (HEC) shoul d be administered 
with antiemet ic prophylact ic therapy  of ondansetron or granisetron plus dexamethasone 
and aprepi tant (≥ 12 years of age and receiving antineoplast ic agents not known to 
interact wi th aprepi tant) or ondansetron or grani setron pl us dexamethasone (< 12 years of 
age or receiving aprepi tant interacting agents). For patients scheduled to receive 
moderately emetogenic chem otherapy (MEC), the recommendation was that patients 
shoul d receive ondansetron or granisetron plus dexamethasone. [10] 
The role of the NK 1recepto r antagonists in children has to be further invest igated. It has 
recent ly been suggested that the addi tion of  the oral  NK 1receptor antagonist aprepitant to 
ondansetron with or wi thout dexam ethasone may be effect ive in the prevent ion of CINV 
in pediatric p atients aged 6 months to 17 y ears receiving MEC or HEC regimens. [11]
Page 242 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 34of 98
CONFIDENTIAL
In adults palonosetron hy drochl orideadministered by the intravenous (IV) and oral routes 
hasa demonstrated efficacy for the management of nausea and vomiting associ ated with 
cancer chem otherapy . Its prol onged durati on of action offers significant advantages over 
other 5-HT 3receptor antagonists. Pharmacol ogical experiments indicate that 
palonose tron interacts with 5-HT 3receptors very different ly than granisetron or 
ondansetron and that this different ial interact ion triggers a receptor alteration or 
internalizat ion resul ting in a long lived inhibit ion of receptor function.These 
pharmaco logical findings may have clinical relevance and contribute to explain the 
extended ant iemetic protection conferred by palo nosetron .[12]
In July 2003 the United States (US) Food and Drug Administration (FDA) approved 
palonosetron 0.25m g IV as a 30-second bolus for the prevention of acute CINV 
associ ated wi th HEC or MEC, and f or prevent ion of delayed CINV associ ated wi th MEC 
(initial and repeat courses) in adults. In Europe, IV palonosetron was approved via the 
Centralized Procedure in March 2005. Palonosetron is registered in several countries wit h 
different trademarks (Alo xi®, Onici t®, Paloxi®). [13]
Safety and efficacy  of palonosetron for the prevent ion of CINV in pediatri c popul ation 
has been so far evaluated in the following clinica l studi es.
The pediatri c study PALO -99-07 [14] evaluated 3 and 10 µg/kg doses of IV pal onosetron 
for prevent ing highly and moderately emetogeni c CINV in the acute phase, in a limited 
number of pediatri c pati ents (n=35, and n=37, respectively). In the pool ed analysis which 
included randomized and open -label patients, the proporti on of patients with a complete 
response (CR; no emesis and no rescue) during the first 24h after chemotherapy was 
higher in the palonosetron 10 µg/kg group than in the 3 µg/kg group (54.1% vs. 37.1%). 
[14]
The efficacy of two different doses of palonos etron was also tested in pediatri c patients 
undergo ing single and repeated cycles of HEC or MEC (PALO -10-20). Overall, the 
efficacy of palonosetron 20 μg/kg was comparable to that of ondansetron, while the 
efficacy of palonosetron 10 μg/kg tended to be slightly lower than that of ondansetron. 
Safety assessments were consi stent wi th the established safety  profiles of pal onosetron in 
adults and did not indicate a significant risk to pe diatric patients receiving HEC or MEC 
for up to 4 consecut ive cycles. [15]
Palonosetron as intravenous formulation at the dosage of 20 µg/kg (max 1.5 mg) infused 
over 15 minutes was approved in the US on May 27th, 2014 for pediatric use in patients 
aged from 1 month to less than 17 years for the preventi on of acute nausea and vomiting 
associ ated with initial and repeated courses of emetogeni c cancer chem otherapy , 
including HEC. Similarly , palonosetron intravenous form ulation with indicat ion of CINV 
prevent ion was extended on February 24th, 2015 in European Economic Area (EEA) to 
pediatric patients 1 m onth of age and o lder.
Helsinn devel oped an oral fixed-dose combinati on (FDC) which includes a 5-HT 3
receptor antagonist (palonosetron, 0.5 mg) and an NK 1receptor antag onist (netupi tant, 
300 mg) in the form of a hard-gelat ine capsule (oral  NEPA FDC) to be administered to 
adults pati ents as a single administration 1 h prior to chemotherapy . 
Page 243 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 35of 98
CONFIDENTIAL
Netupi tant is a new, high-efficient, select ive NK 1receptor antagonist that block s 
receptors located in the central  nervous system  (in the putative vomiting center in the 
nucleus tractus soli tarii) and in the gastrointestinal tract wall (peri pheral abdominal vagal 
afferents) . [16]
The oral  NEPA FDC has been approved in 2014 in the US for the prevent ion of acute and 
delayed nausea and vomi ting in adul t patients associ ated wi th ini tial and repeated courses 
of chemotherapy , including but not limited to, H EC, and in the EU for the prevent ion of 
acute and delayed nausea and vo miting associated with highly emetogenic cisplat in-based 
cancer chemotherapy and moderately emetogenic cancer chemotherapy .[16]
Oral NEPA FDC (Akynzeo®) is current ly officially recommended for MEC and HEC 
acute and delayed emesis prevent ion by the National  Comprehensive Cancer Network 
(NCCN) gui delines in adults. [17]
An IV FDC of palo nosetron and fosnetupitant is meanwhile under clinical development.
The present study  will be a Phase 2 pharmacokinet ic/pharmacodynamic (PK/PD ) dose 
finding study  of oral netupi tant administered conco mitantly with oral palonosetron in 
pediatric cancer patients for the prevent ion of nausea and vomiting associated with 
emetogeni c chem otherapy . This will be part of the pediatri c program  of the oral NEPA 
FDC’s line extensio n, aiming at complying with the post-approval commit ments after 
registrati on of  oral NEPA FDC by FDA. 
1.2 Pre-clinical and Clinical Data of Palonosetron
1.2.1 Pre-clinical Data
For a detailed descripti on of pre -clinical data on palonosetron , reference is made to the 
relevant Invest igator’s Brochure (IB). [13]
1.2.2 Summary of Phase 1 Clinical Data (Human pharmacokinetics)
Pharmacokinet ic in adult subjects
1.2.2.1 Absorption
Following IV administration, an init ial decline in palonosetron plasma concentrati ons is 
followed by slow eliminat ion from the body  with a mean terminal eliminat ion half-life 
(t1/2) of approximately 40 h which is substant ially longer than other 5-HT 3antagonists, 
i.e., ondansetron (4 -6 h), grani setron (5 -8 h), tropisetron (7 h) and dolasetron (7 h). Mean 
maximum plasma concentrati on (Cmax) and area under the concentration -time curve 
(AUC 0-∞) are generally dose-proporti onal over the dose range of 0.3-90 µ g/kg in healt hy 
adult subjects and in adult cancer patients.
Following oral administrati on, palonosetron is well absorbed with its absolute 
bioavailabilit y reaching 97% mean pl asma C maxand AUC are generally dose -proporti onal 
over the dose range of 0.3-90 μg/kg in healthy subjects and in cancer patients. The mean 
time to maximum plasma concentrati on (tmax) after oral solution administration was 
generally 4 -6 h. [13]
Page 244 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 36of 98
CONFIDENTIAL
1.2.2.2 Distribution
Following both oral and IV administrations, palonosetron is widely distributed in the 
body  (volume of distribut ion of approximately 8.3±2.5 L/kg) and approximately 62% is 
bound to human -plasma proteins. Age, hepat ic dysfunct ion or mild to moderate renal 
impairment have no clinically significant effect on the PK of palonosetron although total 
systemic exposure increases by 28% in patients with severe renal impairment compare d 
with heal thy subjects. [13]
1.2.2.3 Metabolism
Palonosetron is eliminated by dual routes; about 40% is eliminated through the kidne y 
and approximately 50% is metabolized to form two primary metabo lites: M9 N-
oxidepal onosetron (AUC approximately  12% of that of the parent drug) and M4 6-S-
hydroxypalo nosetron (AUC approximately  3.8% of that of the parent drug). These 
metabo lites have less than 1% of the 5-HT 3receptor antagonist  activit y of palonosetron. 
In vitro m etabo lism studies have suggested that pal onosetron is metabo lized primarily by 
CYP2D6 and to a l esser extent by CYP3A and CYP1A2. Palonosetron does not inhibi t or 
induce cytochrom e P450 isoenzymes at clinically relev ant concentrations. Metabo lite 
profiling demo nstrated that the metabolism of palonosetron following oral  administrati on 
was consistent with the metabo lism following intravenous administration. [13]
1.2.2.4 Elimination
After a single IV dose of 10 μg/kg [14C]-palonosetron, approximately 80% of the dose is 
recovered within 144 h in the urine, with palonosetron as unchanged active substance 
represent ing approximately 40% of the administered dose. After a single IV bolus 
administration in healt hy Caucasian subjects the total body clearance of palonosetron is 
173±73 mL/min and renal clearance 53±29 mL/min. The low total body clearance and 
large volume of distribut ion resul t in a terminal eliminat ion half-life of approximately 
40h, which is substant ially longer than that of other 5-HT 3 antagonists, i.e., ondansetron 
(4-6 h), granisetron (5 -8 h), tropi setron (7 h) and dol asetron (7 h). Ten percent of pati ents 
revealed a mean terminal  eliminat ion half-life greater than 100 h. Quantifiable 
concentrations of palonosetron following oral administrati on of a single dose (0.75 mg) 
of radiolabeled [14C]-palonosetron were reported for all subjects until at least 120 h and 
between 192 and 216 h post-dose in plasma and urine respect ively, 85% to 93% of the 
total radioactivi ty was excreted in urine, and 5% to 8% was eliminated in feces. The 
amount of unchanged palonosetron excreted in the urine represented approximately 40% 
of the administered dose. In cancer patients, t½ was 48 ± 19 h. After a single- dose of 
approximately  0.75 mg intravenous palonosetron, the total body clearance of 
palonosetron in healthy subjects was 160 ± 35 mL/h/kg (mean ± SD) and renal clearance 
was 66.5 ± 18.2 mL/h/kg. Quantifiable concentrati ons of M9 metabo lite were reported 
for all subjects until at least 24 h and betw een 120 and 144 h post-dose in plasma and 
urine respect ively. [13]
Page 245 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 37of 98
CONFIDENTIAL
Pharmacokinet ic in pediatric patients
In pediatri c cancer patients (PALO -99-07, [14]), IV administration of 3  and 10 µg/kg 
palonosetron was characterized by a rapid distributi on followed by a slower eliminat ion 
phase. Exposure, as measured by C max, AUC 0-t andAUC 0-, was generally  proporti onal or 
slight ly less than dose-proporti onal for the 3 to 10 µ/kg dose levels, across all three 
evaluated age groups (> 28 days to 23 months, 2 to 11 y ears, and 12 to 17 y ears). 
Both clearance and volume of distribut ion appe ared to increase with increasing age. 
These increases were largely due to body weight differences between the three age 
groups. There were no apparent differences in the distribut ion of individual pat ient values 
across the age groups and doses evaluated. Mean terminal eliminat ion half-life values 
ranged from 21 to 37 h across the three age groups (individual values ranging from 
approximately 11 to 81 h) and did not change with dose or age. There was no effect of 
gender on clearance, vo lume of distribut ion or half -life.
In study  PALO -10-20 [15], PK parameters of two different IV doses (10 and 20 µg/kg) of 
palonosetron were determined in pediatri c patients undergoing single and repeated cy cles 
of HEC or MEC. 
Samples f or the PK sub -study  were drawn from  a total  of 95 pati ents (15 in the < 2 years, 
26 in the 2 to < 6 years, 24 in the 6 to < 12 years and 30 in the 12 to < 17 years age 
group). Of these, 64 patients received palonosetron, while 31 received ondansetron.
After a 15 min infusio n, palonosetron PK profiles appear widely comparable for all age 
groups and both dose levels, with a  peak generally reported immediately at the end of 
infusio n, followed by a rapid palonos etron concentration decrease and a much slower 
eliminat ion phase, with a terminal eliminat ion t½of about 20 to 30 h. A significant 
difference in t½(p<0.008) was observed between age groups with a trend toward longer 
t½for older pati ents, al though an underestimated determinati on of  t½in patients aged less 
than 2 years administered with the lowest dose (10 µg/kg) could have influenced the 
statist ical resul t. Both clearance and volume of distribut ion appear to increase with 
increasing age. AUCs values were clearly related to the palonosetron 10 µg/kg and 
palonosetron 20 µg/kg dose levels. A trend toward increased AUC values (both absolute 
and nominal dose -adjusted) wi th age was observed, f or which statistical significance was 
assessed by analysis of variance (ANOVA) for the nominal dose-norm alized AUC 0-∞
(p=0.0027). No clinically relevant differences were however observed in any of the PK 
param eters reported between genders or types of chem otherapy. The analyses do not 
indicate that the PK of palonosetron are strictly dependent on patient age Therefore, no 
further adj ustm ent of  dosing, bey ond dosing pal onosetron on an individual pati ent weight 
basis, i s requi red for pedi atric pati ents.
In conclusio n, a PK/PD analysis of the resul ts indicated no clear relationship between 
drug exposure and response in pediatri c pati ents in the tested IV dose range. None of the 
patient factors tested, i ncluding body  weight, age, gender, chemotherapy  regimen, or total 
dose administered, had an impact on the response variables (CR in the acute and the 
delayed phase).
Page 246 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 38of 98
CONFIDENTIAL
1.2.3 Clinical Data
Efficacy data in adult patients
In a Phase II study  (Study  2330) following HEC, the four highest palonosetron IV doses 
(3, 10, 30 and 90 µg/kg) were approximately equally effect ive, with the percentage of 
patients with CR ranging from 40% to 50% in comparison to the lowest dose cohort 
(24%; 0.3 to 1 µg/kg). This efficacy profile suggests a plateau in dose response for 
palonosetron when administered at doses greater tha n 3 µg/kg (approximately a 0.25 mg 
fixed dose). Evaluat ion of the secondary  efficacy  variables confirmed the clinical efficacy 
of palonosetron treatm ent at all tested doses with respect to the lowest dose level. 
Palonosetron was well tolerated at all dose levels. Adverse events (AEs) were essenti ally 
equally distributed across the dose groups, and no dose-related safet y relati onship was 
apparent.
Three Phase III studi es with IV palonosetron in both moderately and highly emetogeni c 
patient popul ations (PALO -99-03, PALO -99-04 and PALO -99-05) evaluated doses of 
0.25 mg and 0.75 mg (corresponding to 3 µg/kg and 10 µg/kg). These studi es 
demonstrated that the 0.25 mg dose was the lowest effect ive dose, with no significant 
difference in safet y profile between the doses. In 2003, the 0.25 mg dose was approved 
for market ing in the US, followed later by registrati on in several countri es worldwide. 
[13]
Efficacy data in pediatric patients
The study  PALO -99-07 [14] evaluated 3 and 10 µg/kg doses of IV palonosetron for 
prevent ing highly and moderately emetogeni c CINV in the acute phase in thefollowing 
pediatric age groups: > 28 days to 23 months, 2 to 11 years, and 12 to 17 years of age. 
Recognizing the overall sample size was limited (n=35, and n=37, respect ively), in the 
pooled analysis which included rando mized and open -label patients, theproporti on of 
patients with a CR (no emesis and no rescue) during the first 24 h after chem otherapy 
was higher in the palonosetron 10 µg/kg group than in the 3 µg/kg group (54.1% vs. 
37.1%). 
The study PALO-10-20 [15] was a multicenter, active -controlled, double -blind, 
rando mized, parallel group, stratified, doubl e-dummy , Phase 3 study  involving 3 study 
groups receiving pal onosetron in two different doses or ondans etron standard therapy for 
the prevent ion of CINV. The lower pal onosetron dose was 10 µg/kg up to a m axim um of 
0.75 mg, and the higher palonosetron dose was 20µg/kg up to a maximum dose of 1.5 
mg. The ondansetron dose was 0.15 mg/kg given three times (eve ry 4 h -maximum dose 
of 32 m g).
The primary object ive of this study  was to eval uate the efficacy of two different doses of 
IV palonosetron, compared to ondansetron, in the prevention of CINV in pediatri c 
patients receiving HEC or MEC through 120 h after start of chemotherapy in single and 
repeated chemotherapy cycles. A total of 494 patients were treated with study  drug 
(167 palonosetron 10 µg/kg, 163 palonosetron 20 µg/kg and 164 ondansetron). Patients 
were stratified per age group (< 2 years, 2 to < 6 years, 6 to < 12 years and 12 to 
<17years) and by emetogenicit y (MEC and HEC). 
Page 247 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 39of 98
CONFIDENTIAL
At Cycle 1, the CR in the acute phase of the first study  cycle in the Full Analysis Set 
(FAS) popul ation was reported f or 54.2% of  patients treated wi th palonosetron 10 µg/kg, 
59.4% of  patients treated with palonosetron 20 µg/kg and 58.6% of patients treated with 
ondansetron. These resul ts indicated an effect of palonosetron 10 µg/kg that was 
numerically lower, but comparable to that of ondansetron and an effect of palonosetron 
20 µg/kg that was numerically similar or comparable to that of ondansetron. Similar 
resul ts were obtained in the As Treated and Per Protocol popul ations, with the latter 
showing a numerically higher effect of palonosetron 20 µg/kg compared to that of the 
other treatm ent groups. The study  supported the concl usion that palonosetron is non-
inferi or to ondansetron for the prevent ion of acute CINV. In patients receiving HEC, CR 
was the highest in the palonosetron 20 µg/kg group and the lowest in the palonosetron 
10µg/kg in each age group, except in the 2 to < 6 years group where the highest response 
was shown by palonosetron 10 µg/kg. In the HEC strata, CR rate of palonosetron 
20µg/kg was higher than ondansetron in each age group. In patients receiving MEC, 
oppo site resul ts were observed in the 2 to < 6 y ears age stratum . In contrast, the CR rate 
was higher in the ondansetron group than in either palonosetron groups in the 0 to < 2, 
6to < 12 and 12 to < 17 years age strata. For patients receiving HEC, the CR rate in the 
delayed phase was notably higher in the palonosetron 20 µg/kg group, while for patients 
receiving MEC the CR rates were comparable across treatment groups.
In line with results observed at Cycle 1, throughout study  Cycles 2 to 4, and across all 
phases, the palonosetron 20 µg/kg treatm ent group reported in the majo rity of the cases 
the highest CR rate, the highest proportions of patients with no vomit ing, pati ents wi th no 
emetic episodes and pati ents wi th no use of anti emet ic rescue medicat ions. Likely due to 
the progressively lower number of patients, different response rates were reported across 
the cycles, and statistical significance could not be ascertaine d for these compar isons as 
indicated by  overlapping 95% CIs.
Safety in adult patients
In adult patients, AEs considered by investigators to be related to palonosetron were 
consistent with those observed for other 5-HT 3receptor antagonists as a class or with 
those expected in a cancer or surgical popul ation, with occasi onal very minor, non-
clinically relevant differences between palonosetron and marketed active comparators 
[13]. Constipat ion and headache were the most frequent ly observed AEs in patients 
receiving IV or oral palo nosetron. These AEs are frequent ly reported in patients receiving 
5-HT 3receptor antagonists for the prevent ion of nausea and vomiting associ ated with 
cancer chemotherapy or for the prevent ion of post-operative nausea and vomiting 
(PONV).
The result s of a thorough QT/QTc study  (Study  PALO -03-11) in adul t healthy volunteers 
demonstrated that palonosetron is not associated with QT prolongat ion at doses up to 
2.25 mg, which provides a 9-fold safet y margin for the approved market dose for CINV 
IV indicat ion, 0.25 m g for adul ts. [13]
Safety in pediatric pat ients
As for the pediatric use of palonosetron, its safety has been invest igated in two CINV 
studi es (PALO -99-07, PALO -10-20) [14, 15], in children aged between 1 month and 
Page 248 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 40of 98
CONFIDENTIAL
17years, receiving HEC or MEC, who were administered 3, 10 or 20 µg/kg, up to a 
maximum total fixed dos e of 0.25, 0.75 m g or 1.5 mg, respectively.
The safet y profile of palonosetron has been also assessed in two PONV studi es (PALO -
07-29, PALO -10-14) [18, 19], in pediatri c patients aged > 28 days up to 16 years 
inclusive, undergoing elective surgical procedures requi ring general endotracheal 
inhalat ion anesthesia, who were admin istered 1 or 3 µg/kg, up to a maximum total fixed 
dose of 0.075 or 0.25 mg, respect ively. 
In these studi es, palonosetron was safe and well tolerated at all tested doses, no relevant  
clinical findings were observed, confi rming its safet y and efficacy in the prevent ion of 
CINV and PONV in pediatric populat ion. [14, 15, 18, 19]
In study  PALO -10-20, clinically relevant differences between treatm ents in the safet y 
profile were not observed in the overall study  population or in subgroups of patients 
based on age, gender, race, ethnicit y or emetogenicit y of chemotherapy. Safet y 
assessments in this study  were consistent with the established safet y profiles of 
palonosetron and ondansetron in adul ts and did not indicate a significant risk to pediatri c 
patients receiving HEC or MEC for up to 4 consecutive cycles.
Overall, palonosetron was safe and well tolerated at all dosages empl oyed in clinical 
trials, and no remarkable differences were observed for any safet y parameters in both 
adults and pediatri c pat ients. [13]
For further information about palonosetron, including pharmacokinet ics, 
pharmacodynamics, clinical efficacy and safet y, please refer to th e current edition of th e 
IB. [13]
1.3 Pre-clinical and Clinical Data of Netupitant
1.3.1 Pre-clinical data 
1.3.1.1 Netupitant
A detailed descripti on of the netupi tant animal data is provided in the current IB for the 
oral NEPA FDC. [16]
1.3.2 Summary of Phase 1 Clinical Data (Human pharmacokinetics) of 
Netupitant
1.3.2.1 Absorption
In single dose oral studies conducted with the administration to healt hy volunteers, 
measurable plasma netupi tant concentrations were detected between 45 minutes and 3 h 
after dosing. Pl asma concentrati ons followed a first order absorpti on process and reached 
Cmaxin approximately 5 h. [16]
1.3.2.2 Distribution
The mean apparent vol ume of  distribut ion (Vd) of netupi tant in humans generally ranged 
from 850 L to over 2000 L, indicat ing substantial distribut ion to tissues. The drug is 
Page 249 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 41of 98
CONFIDENTIAL
highly bound to plasma proteins (> 99%) with apparent lyno large differences in free 
fraction between healt hy subjects and pat ients with hepat ic failure. [16]
1.3.2.3 Metabolism
Netupi tant is primarily excreted via hepat ic/biliary routes, with renal clearance (CL R) 
accounting for less than 5% of CL. Netupi tant is metabo lized by CYP3A4 to severa l 
metabo lites. The PK of a single 300 mg dose of netupitant was not affected by co-
administration of the CYP3A4 substrates erythromycin (500 mg) or midazolam (7.5 mg). 
However, netupitant appears to inhibit the metabolism of both these substrates, resulting in 
an increase in exposure of erythromycin and midazolam proving that netupitant inhibits 
CYP3A4. Other CYP450 isoenzymes (CYP1A2, CYP2 C19, CYP2D6) are not inhibited 
by netupi tant. Netupi tant i s not an inducer of any CYP450 i soform including CYP2C9. In 
human liver microsomes, netupi tant competitively inhibit ed the CYP3A4 mediated 
hydroxylation of testosterone and midazo lam (apparent Ki of1.1 and 2.2 µM, 
respectively ). Therefore, interacti ons of netupi tant with drugs mainly metabo lized by 
CYP3A4, were evaluated in addition to other agents likely to be co-administered with 
netupi tant, in the treatm ent of highly or moderately  emetogeni c CINV . [16]
Four metabolites have been identified in human plasma at netupi tant doses ≥ 30mg; 
metabo lites M1, M2, and M3 are considered majo r metabolites. In a human radiolabeled 
absorpti on, distributi on, metabo lism, and excret ion (ADME) study on oral netupi tant, 
M1, M2 and M3 accounted for 29%, 14% and 33%, respectively, of total plasma 
radioactivi ty exposure (AUC). Exposure for M4 accounted for <10% of the parent. 
Medi an tmaxfor metabo lite M2 was 5 h and was about 17-32 h for M1 and M3. Oral 
netupi tant, and its 3major metabo lites are extensively bound (> 97%) to plasma protein 
and all metabo lites have been shown to be pharmacologically act ive. [16]
1.3.2.4 Elimination
The apparent mean eliminat ion half-life of netupi tant generally ranged from 30 to 
approximately 100 h (for oral doses of 30 mg to 450 mg). There was a slight ly supra -
proporti onal increase in C maxand AUC parameters for doses from 10 m g to 300 m g with 
dose proporti onal increases between 300 mg and 450 m g. No trends of CL or Vd changes 
were seen wit h increases in dose. [16]
1.3.3 Clinical Data 
1.3.3.1 Netupitant Alone or in Combination with Palonosetron
The oral formulation of netupi tant, as single agent or in combination with other 
compounds, including the 5-HT 3receptor antagonist palonosetron, has been invest igated 
in 27 studi es; 20 of them were conducted in healt hy adult volunteers. A total of 
1,939 adult subjects and patients received netupi tant in combinat ion with palonosetron 
and 206 adult subjects and pat ients received oral netupi tant al one.
Oral netupi tant was generally well tolerated at all dose levels tested. In healt hy 
volunteers, the most frequent ly reported treatment -emergent adverse events (TEAEs) 
related to netupitant alone (not in combinat ion) were headache, fatigue, somnolence, 
Page 250 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 42of 98
CONFIDENTIAL
nausea, asthenia, lethargy , diarrhea and abdominal pain. In phase 2 and phase 3 studies in 
cancer patients, the oral NEPA FDC showed a good safet y profile and proved to be 
effect ive for the preventi on of acute and delayed nausea and vomiting associ ated with 
initial and repeated courses of MEC and HEC. [16]
In the Phase 2 and Phase 3 studi es, leading to oral NEPA FDC (Akynzeo®) approval , the 
type, frequency and intensity of AEs were comparable across treatm ent groups. There 
was no apparent dose-response effect and the safety  profile of the oral NEPA FDC was 
similar to that of other dose combinations, to that of palonosetron alone and to that of 
aprepi tant in combinat ion with ondansetron or palonosetron (com parators in the Phase 2 
and 3 studi es). There were no clinically significant changes in laboratory  parameters. No 
clinically significant changes in vit al signs were reported across all studi es. All data 
regard ing electrocardiograms (ECGs) and QT intervals suggest no clinically relevant 
effects for QT prol ongat ion in the Phase 1, Phase 2 and Phase 3 studi es and in a thorough 
QTc study .
Further details are provided in the current IB of oral NEPA FDC. [16]
Pediatric studies have not been performed so far on the netupi tant alone, or as a 
component in combinat ion such as Akynzeo®.
1.4 Study Rationale
This study  (NEPA -15-31) will be a Phase 2 PK/PD dose-finding study  of oral netupi tant 
administered conco mitantly with oral palonosetron in pediatri c cancer patients for the 
prevent ion of nausea and vomiting associ ated with emetogeni c chem otherapy. This will 
be part of the pediatric program  of the oral NEPA FDC’s line extensio n, aiming at 
complying with the post-approval commit ments after registrati on of oral NEPA FDC 
(Akynzeo®) by US FDA. 
The select ion of the netupi tant doses to be used in this study  is supported by  efficacy  and 
safet y data in adults from Akynzeo®pivotal  studies NETU -07-07 (HEC) [20] and 
NETU -08-18 (MEC) [21]. In those studi es, the efficacy and safet y of oral netupi tant 
doses of 100, 200 and 300 mg (NETU -07-07 [20]) and 300 mg (NETU -08-18 [21] and 
NETU-10-29 [22]) in co mbinat ion with oral palonosetron (0.5 m g) were assessed.
During the devel opment of  oral Akynzeo®, netupi tant doses of 100, 200, 300 and 450 mg 
have been tested in the adult popul ation (see studies NP16601, NP16603, NETU -06-27, 
NETU -06-07, NETU -07-01, NETU -10-29). All doses proved to be well tolerated and 
doses of 100 and 300 mg showed antiemetic efficacy in pivotal clinical trials in cancer 
patients undergoing emetogenic chemotherapy treatments. [16, 20, 21, 22] 
In this study  (NEPA -15-31), the following two different netupi tant dosages will be tested
in patients aged from 3 months to < 18 years : 1.33 mg/kg up to a maximum of 100 mg, 
and 4 mg/kg up to a maximum of 300 mg. Because netupi tant eliminat ion is mainly 
mediated by CYP3A4 metabo lism, due to CYP3A4 ontogeny  (where CYP3A4 capacit y 
in 12 month olds is about 40% of adult levels), the youngest patient age classes 
(<3months of age) will be treated at lower doses: i.e., 0.8 mg/kg and 2.4 mg/kg. All 
Page 251 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 43of 98
CONFIDENTIAL
netupi tant doses in all age classes will be conco mitantly administered with palonosetron 
20µg/kg (up to a maximum dose of 1.5 m g).
Study  NEPA -15-31 is planned to be the first pediatri c clinical trial involving netupitant, 
together with oral palonosetron. A single oral palonosetron dose of 20 µg/kg (up to a 
maximum dose of 1.5 mg) will be used in this study . This corresponds to the IV 
palonosetron dose approved by  USA FDA for the pedi atric populati on. The approval  was 
based on efficacy and safet y data from IV palonosetron study  PALO -10-20 [15] in 
pediatric patients (HEC/MEC) aged 1 month to < 17 years. Since the absolute 
bioavailabilit y of oral palonosetron is approximately 97% in adult subjects (as stated in 
IV Aloxi®labeling), similar safety and efficacy as demonstrated in PALO-10-20 [15] is 
expected in NEPA -15-31 from the 20 µg/kg palonosetron component given as an oral 
solution.
The role of corticosteroi ds in concomi tance with 5-HT 3and NK 1receptor antagonists to 
prevent CINV is controversi al and less well established in pediatric cancer patients when 
compared to adul ts, partially because they are comm only used in pediatri c popul ation as 
part of chemotherapy regimens . [2]
Overall, a number of common pediatri c chem otherapy  regimens include a corticosteroi d, 
usually prednisone or dexamethasone, as an essent ial component of chemotherapy. [2]
Netupitant is expected to increase systemic exposure to dexamethasone and predniso ne. 
[23]
Moreover, due to the interaction, pediatric onco logists m ay decide not to u se netupitant in 
pediatric cancer patients receiving dexamethasone or prednisone as part of their 
chemotherapy. The same safet y concerns are true for other clinical trials with any NK 1
receptor antagonist given wit h steroi ds, and these were also reported i n previous pediatri c 
CINV trials wit h aprepitant. [11]
The Sponsor has concerns to safely enroll a “broader” populat ion involving pediatri c 
patients receiving systemic corticosteroi ds as part of their chem otherapy regimen, even 
though it is recognized that these safet y considerati ons may reduce the pool of pediatric 
cancer patients available to enroll in NEPA -15-31. 
Therefore, any pediatri c patients receiving systemic corticosteroi d therapy  started within 
72 h prior to study drug administration and/or scheduled to receive a corticosteroi d as 
part of  their chem otherapy regimen during the study  should not be eligible for this study 
since there are too many  risks and unknowns.
Page 252 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 44of 98
CONFIDENTIAL
2STUDY OBJECTIVES
2.1 Primary
The primary  object ive is to invest igate the PK/PD correl ation between netupi tant 
exposure and antiemetic efficacy  after a single oral netupi tant administration, 
concomitant ly with oral palonosetron in pediatri c cance r pati ents receiving MEC or HEC 
treatm ents. Efficacy parameter to be used in the correlati on is the proporti on of patients 
with CR (i.e., no emetic episodes and no rescue medicat ion) during the delayed phase 
(>24-120 h after the start of chemotherapy on D ay 1).
2.2 Secondary
The secondary  objectives are the following:
-to assess the safet y and tol erabili ty after single oral  administrati on of  netupi tant given 
concomitant ly with a single oral  administrati on of  palonosetron;
-toevaluate the PK profile of oral palonosetron at the fixed dose of 20 µg/kg in 
pediatric patients with the concomitant administratio n of netupitant.
Page 253 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 45of 98
CONFIDENTIAL
3STUDY PLAN
3.1 Study Design
This is a multicenter, mult inational, rando mized, double -blind, stratified (by  age class; by 
emetogeni city; by chem otherapy schedule), dose-finding, Phase 2 study  involving two 
treatm ent groups receiving a single oral dose of netupi tant administered conco mitantly 
with oral palonosetron. 
The study  is planned to be performed at a minimu m of approximately 16 sites in USA, 
Russia, Ukraine and Serbia; more sites and/or countries may  be added if necessary.
A total of 92 pediatri c cancer patients receiving either HEC or MEC will be enrolled in 
the study . 
The patients will be enrolled into on e of two netupitant dose treatm ent groups 
(46patients/group): 
Treatment group 1: from 1.33 mg/kg up to a maximum of 100 mg (for patients 
< 3months of age the netupitant dose will be 0.8 mg/kg)
Treatment group 2: from 4 mg/kg up to a maximum of 300 mg (for patients 
< 3months of age the netupitant dose will be 2.4 mg/kg)
Each netupi tant dose is administered with 20 µg/kg palonosetron (up to a maximum of 
1.5 m g).
The study  will be stratified by the following criteria:
Age class:
•Birth to < 1 m onth 
•1 to < 3 months 
•3 to < 6 months 
•6 to < 12 months 
•1 to < 2 y ears 
•2 to < 5 y ears
•5 to < 12 y ears 
•12 to < 18 y ears 
Emetogenicit y:
•HEC
• MEC
Chem otherapy  schedule:
•HEC/MEC on Day  1 only
•HEC/MEC on mult iple days 
Within each stratum , patients will be randomized prior to study drug administration to 
one of the two previously ment ioned netupi tant treatm ent groups. 
Page 254 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 46of 98
CONFIDENTIAL
An except ion will be the younger age classes (all age classes < 12 months) for which the 
safet y of the lowest netupi tant dose(s) will be evaluated before escalat ing to the 
subsequent netupi tant dose groups. For these age classes the Emetogeni city and 
Chem otherapy  schedule strata will not be considered, even not when rando mizat ion will 
start i n relevant cl ass.
The treatment plan is described in detail here below and is summarized in Appendix 1.
At the beginning of the study  enro lment is open only to:
-patients aged 1 year, who will be rando mized to one of the two netupitant doses 
-patients aged 6 months to < 12 months who will be treated with the netupi tant lower 
dose (1.33 mg/kg)
At the beginning of the study  three patients aged 6 to < 12 months will be first enrolled 
in the lower netupi tant dose group (1.33 mg/kg). As soon as these first 3 patients have 
completed the study , without saf ety and tolerabilit y concerns as assessed by Data Safety 
Moni toring Board (DSMB), enrolment in the higher netupi tant dose group (4 mg/kg) of 
the sam e age class (6 to < 12 months) can start. 
As soon as 6 patients in the age class 6 to < 12 months (3 patients for each netupi tant 
dose group) have completed the study  without safet y and tolerabili ty concerns, decision 
by DSMB will have to be take n whether a) all remaining patients 6 to <12 m onths can be 
rando mized to one of the two netupi tant treatm ent doses and start the assigned treatm ent, 
and b) the lower age class 3 to < 6 months may start the treatment with the lower dose. 
The enrollment of the remaining cohorts will occur in parallel keeping the original 
treatm ent dose escalati on scheme: 3 patients will be fi rst treated wi th the l ower netupi tant 
dose. As soon as these first 3 patients will have completed the study and no safet y and 
tolerabil ity concerns are shown, as assessed by the DSMB, enrolment in the higher dose 
group in the same age class will start [37].
3.2 Study Duration
The planned durati on of the study is a maximum of 31 days for each patient, which 
includes screening up to 14 days before rando mization (up to 7 days for patients aged 
< 2years), day of enrolment/rando mizat ion, administration of study drugs and 
chemotherapy (Study  Day 1), and the PK vi sit (Study  Days 2 to 5). The final visi t will be 
6, 7 or 8 days after study  drug administration, and a follow up visit / telephone contact 
will be performed between 14 and 17 days after study  drug administration. 
3.3 Study Population
Male and female pediatri ccancer patients from birth up to < 18 years, scheduled to 
receive HEC or MEC to be administered as single day chem otherapy on Day 1 only or 
for multiple days .
Page 255 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 47of 98
CONFIDENTIAL
3.3.1 Number of Patients
The number of patients to be treated is estimated to be 92, distributed in two treatment 
groups (i.e., 46 patients/group). For each age class included in the stratificat ion, the 
relevant pl anned number of patients to be enrolled is provi ded bel ow. For the sample size 
calculat ion please refer to Section 8.1Sample Si ze Determinat ion.
Age classes Number of patients 
to be included
Birth to < 1 month 12
1 to < 3 months 12
3 to < 6 months 8
6 to < 12 months 8
1 to < 2 years 8
2 to < 5 years 12
5 to < 12 years 16
12 to < 18 years 16
Overall 92
3.3.2 Inclusion Criteria
Patients m ust meet the fo llowing cri teria to be eligible to participate in the study : 
1.Signed written informed consent by parent(s)/l egal guardians of the pediatric patient 
in compliance with the local laws and regulat ions. In addition signed children’s 
assent form according to local requirements.
2.Male or female in-or out-patient from birth to < 18 years at the time of 
rando mizat ion.
3.Patient wei ght at least 3.3 kg.
4.Naïve or non-naïve patient with histol ogically, and/or cytologically (or imaging in 
the case of brain tumors or nephroblastoma ) confirmed malignant disease.
5.Scheduled and eligible to receive at least one moderately or highly emetogeni c 
chemotherapeut ic agent on Day 1 only or for mult iple days (Appendix 2).
6.For patient aged ≥ 10 years: Eastern Cooperative Onco logy Group Perform ance 
Status (ECOG PS) ≤ 2 (Appendix 3).
7.Adequate hepat ic function defined as serum ALT and AST ≤ 2.5 ULN, and total 
bilirubin ≤ 1.5 ULN.
8.Adequate renal funct ion defined as est imated glomerular filtration rate (eGFR) ≥ 70 
ml/min/1.73m2(≥ 50 ml/min/1.73m2for children < 3 months ol d). The eGFR sh ould 
be calculated using the modified Schwartz equation (Appendix 5).
9.For patient with known history  or predisposit ion to cardiac abnormalit ies: in the 
Invest igator’s opinion the history /predisposi tion shoul d not jeopardi ze patient’s 
safet y during the study .
Page 256 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 48of 98
CONFIDENTIAL
10.If the patient is female, she shall: a) not have attained menarche yet or b) have 
attained menarche and have a negat ive pregnancy test at the screening visit and at
Day 1. 
11.Male or female fertile patient using reliable contraceptive measures (such measures, 
for patient and sexual partner, include: implants, injectables, combined oral 
contraceptives, intrauterine devices, vasectomized/sterilized partner, use of a doub le-
barrier method or sexual abstinence). The patient and his/her parent(s)/l egal 
guardi ans must be counseled on the importance of avoiding pregnancy before or 
during the study .
All inclusion criteria will be checked at screening visit (Visit 1). In clusion criteria #3, 5, 
10 will be re -checked at Day  1 (Vi sit 2).
Local  laboratory  results from an appropri ately certified local laboratory  could be used at 
the discret ion of Investigator to evaluate patients’ eligibilit y.
3.3.3 Exclusion Criteria
Patients who m eet any  of the f ollowing cri teria will not be eligible for admission into the 
study :
1.The patient and/or parents/caregivers are expected by the Investi gator to be non-
compliant wi th the study  procedures. 
2.Patient has received or is scheduled to receive total body irradiat ion, total nodal 
irradi ation, upper abdo men radiotherapy , half or upper body  irradiat ion, radiotherapy 
of the cranium , crani ospinal regi ons, head and neck, l ower thorax regi on or the pelvis 
within 1 week pri or to s tudy entry  (Day 1) or wi thin 120 h after start of chem otherapy 
administration on Day  1. 
3.Known history  of allergy to any  component or other contraindicat ions to any  NK 1or 
5-HT 3receptor antagonists.
4.Active infection.
5.Any illness or condi tion that, in the opini on of  the Invest igator, may pose 
unwarranted risks in administering the invest igational product to the patient .
6.Patient suffering from ongoing vomiting from any organic etiology (including 
patients with history  of gastri c outlet obstructi on or intestinal obstructi on due to 
adhesio ns or volvulus, pat ients with a symptomatic CNS tum or causing nausea and/or 
vomiting) or patient with hydrocephalus.
7.Patient who experienced any vomiting, retching, or nausea within 24 h prior to the 
administration of the study  drug (note: functional vomiting for infants, which is 
norm ally seen during the first 3 months of life, is not to be considered as vomit ing).
8.Patient who received any drug with potenti al anti-emetic effect within 24 h prior to 
the start of reference chemotherapy, including but not limited to:
-NK 1-receptor antagonists (e.g., aprepitant or any  other new drug of this class);
- 5 -HT 3receptor antagonists (e.g., ondansetron, granisetron, dolasetron, tropisetron, 
ramosetron);
-Benzamides (e.g., metoclopramide, alizapride);
-Phenothi azines (e.g., prochlorperazine, prom ethazine, perphenazine, 
fluphenazine, chlorpromazine, theithylperazine);
Page 257 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 49of 98
CONFIDENTIAL
-Benzodi azepines initiated 48 h prior to study drug administration or expected to 
be received within 120 h following initiation of chemotherapy, except for single 
doses of midazo lam, temazepam  or tri azolam;
-Buty rophenones (e.g., droperido l, haloperi dol);
-Anticholinergics (e.g., scopolamine, with the except ion of inhaled 
anticholinergics for respiratory disorders, e.g., ipratropium bromide); 
-Antihistamines (e.g., diphenhydramine, cyclizine, hydroxyzine, 
chlorphenhyramine, dimenhydrinate, meclizine);
-Dom peridone; 
-Mirtazapine; 
-Olanzapine ;
-Prescribed cannabino ides (e.g., tetrahydrocannabinol, nabilo ne);
-Over the Counter (OTC) antiemet ics, OTC cold or OTC allergy medica tions;
-Herbal preparations containing ephedra or ginger.
9.Patient who received palonosetron within 1 week prior to administration of study 
drug. 
10.Patient who has been started on systemic corticosteroi d therapy  within 72 h prior to 
study  drug administrati on or is planned to receive a corticosteroi d as part of the 
chemotherapy regimen.
Except ions:
-Patient who is receiving chronic (> 72 h), daily steroi d therapy can be enrolled 
provi ded the steroi d dose is not > 0.14 m g/kg (up to 10 m g) of  prednisone daily or 
equivalent.
-For supporti ve care, patient is permi tted to receive a single dose of corticosteroi d 
during the 72 h prior to study drug administration (but not < 12 h prior to study 
drug administration) provi ded it is less than the equivalent of 20 mg of 
prednisone.
11.Patient aged < 6 years who received any investigational drug (defined as a 
medicat ion with no marketing authori zation granted for any age class and any 
indicat ion) wi thin 90 days pri or to Day  1, or pati ent aged 6 years who received any 
investigat ional drug within 30 days prior to Day 1  o r is expected to receive 
investigat ional drugs prior to study  com pletion.
12.Intake of alcohol, food or beverages (e.g., grapefruit, cranberry , pomegranate and 
aloe vera juices, Germ an cham omile) known to interfere with either CYP3A4 or 
CYP2D6 metabo lic enzymes within 1 week prior to Day 1 and during the overall 
study  period (Appendix 4).
13.Use of any drugs or substances known to be strong or moderate inhibitors of 
CYP3A4 and CYP2D6 enzymes wi thin 1 week pri or to Day  1 or pl anned to be used 
during the overall study  period (Appendix 4).
14.Use of any drugs or substances known to be CYP3A4 substrates with narrow 
therapeuti c range within 1 week prior to Day 1, or planned to be used during the 
overall study  period (Appendix 4).
15.Use of any drugs or substances known to be inducers of CYP3A4 enzymes within 
4weeks prior to Day 1 or planned to be used during the overall  study period 
(Appendix 4).
Page 258 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 50of 98
CONFIDENTIAL
16.Lactating female pat ient. 
17.Patient wi th clinically  relevant Grade 3 or 4 non-hematological abnormal  laboratory  
values.
20.Enrolment in a previous study  with netupi tant (either alone or in combination with 
palonosetron).
21.Marked baseline prolongat ion of QTc interval [QTcB or QTcF > 460 msec] at 
screening.
NOTE: Exclusio n criteria ## 18 and 19 were skipped intentionally  to maintain 
consistency in exclusio n criteria numbering between protocol amendments.
All exclusio n criteria will  be checked at screening visit (Visi t 1). Excl usion criteria #2, 4, 
7, 8, 9, 10, 11, 12, 13, 14, 15, 17, 21 will be re -checked at Day  1 (Visi t 2). In case of ERT 
central  ECG report pending, the assessment of compliance with exclusio n criterion #21 
could be made based on autom atic interpretati on of QTcB and QTcF resul ts by ECG 
machine at the discretion of Invest igator.
All eligible pat ientsmust be approved for randomization by authori zed Medical  Moni tor.
Page 259 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 51of 98
CONFIDENTIAL
4STUDY DRUG MANAGEMEN T
4.1 Description of Investigational Medicinal Products
The fo llowing investigational medicinal products (IMPs) will be used during the study :
Name: Oral Netupitant (IMP 1)
Dosage form : glass vial wit h liquid formulat ion (suspensio n)
Strength: 100 m g netupi tant / 7 mL
Dosing : netupi tant will be administered based on the body weight as a 
single oral  dose 1 h (± 10 minutes) pri or to s tart of emetogeni c 
chemotherapy on Day  1
Route of administration: oral
Name: Oral Netupitant (IMP 2)
Dosage form : glass vial wit h liquid formulat ion (suspensio n)
Strength: 300 m g netupi tant / 7 mL
Dosing : netupi tant will be administered based on the body weight as a 
single oral  dose 1 h (± 10 minutes) pri or to s tart of emetogeni c 
chemotherapy on Day  1
Route of administration: oral
Name: Oral Palonosetron (IMP 3)
Dosage form : glass vial wit h liquid formulat ion (solut ion)
Strength: 0.75 mg palonosetron / 5 mL (oral  administrati on of the 
0.75 mg/5 mL so lution for IV use)
Dosing : palonosetron will be administered based on the body  weight at 
the dosage of 20 µg/kg (max 1.5 mg), immediately (within 5 
minutes) after netupi tant, i.e., 1 h (± 10 minutes) prior to start 
of emetogenic chemotherapy on Day  1
Route of administration: oral
Page 260 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 52of 98
CONFIDENTIAL
4.2 Treatment Groups
A total of 92 pediatri c cancer patients will be enrolled to one of two treatment groups 
(46patients/group): 
-Treatment group 1–patients≥ 3 months of age will receive a single oral 
netupi tant dose of 1.33 m g/kg (up to a m aximum  of 100 mg for pati ents wei ghting 
75 kg or more) concomitant ly with a single oral palonosetron dose of 20 µg/kg 
(up to a maximum of 1.5 mg for patients weighting 75 kg or more). For patients 
<3 months of age, the netupitant dose will be 0.8 mg/kg.
-Treatment group 2–patients ≥ 3 months of age will receive a single oral 
netupi tant dose of 4 mg/kg (up to a maximum of 300 mg for patients weighting 
75 kg or more) conco mitantly with a  single oral palonosetron dose of 20 µg/kg 
(up to a maximum of 1.5 mg for patients weighting 75 kg or more). For patients 
<3 months of age, the netupitant dose will be 2.4 mg/kg.
4.3 Dose and Administration
The netupi tant doses to be tested in the pediatric popul ation will  match exposures to adul t 
doses of 100 up to 300 mg as tested in pivotal Phase 2 trial NETU -07-07 [20], and 
300mg as tested in pivotal Phase 3 trials (NETU -08-08 [21] and NETU -10-29 [22]. 
These doses proved to be safe and effect ive. Basic assumpt ion behind this choice is that 
efficacious netupi tant AUC values in children are similar to those observed in adults at 
effect ive doses. 
In order to predi ct the pedia tric doses matching exposures to adul t doses of  100 and 300, 
CL/F values in different age classes were est imated by pharmacokinet ic allo metry  scaling 
according to the fo llowing m odel:
(CL/F)p = ( CL/F)a ∗  BWp
70    
where (CL/F)p and (CL/F)a are the systemic clearances in pediatri c patients and adults, 
respectively , BW p is the body weight of  children, 70 is the standard adul t BW  expressed 
in kg, and ADE is an age -dependent exponent [24]. ADE values across the age classes 
were assumed to be the following [24]: 1.2 for children aged ≤ 3 months, 1.0 for those 
aged > 3 months to 2 years, 0.9 for those aged > 2 years to 5 years, and 0.75 for those 
aged > 5 years. The model accounts for the effect of the body  size change and organ 
maturati on. An age -dependent exponent that decreases wit h the age increase, is consistent  
with a faster funct ional maturation occurring during the y oungest age ranges. 
Reference body  weights for children were taken from growth charts compiled by the 
CDC (Centers for Disease Control and Prevention, Atlanta, GA, USA) [25].
Average AUC values in adults receiving 100 and 300 netupi tant have been calculated by 
dividing these doses by the geometric mean of netupi tant clearance in adults, 
(CL/F)a =20.27 L/h, obtained from the popul ation PK study (Study  NETU -10-02 [26]), 
assuming linear kinet ics. The netupi tant doses for each pediatri c age classes that are 
expected to y ield these target AUC val ues have been calculated by multiplying AUCs by 
Page 261 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 53of 98
CONFIDENTIAL
the respective predi cted CL/F in children, assuming the same netupi tant oral 
bioavailabilit y (F) in pediatri c pat ients and adults. 
In conclusio n, netupi tant doses per age class to be tested in the PK/PD -based dose finding 
study  in pediatri c pat ients resul ted to be the following:
Age classDose 1
(mg/kg)Dose 2
(mg/kg)
Birth to < 1 month 0.8 2.4
1 mo nth to < 3 mo nths 0.8 2.4
3 mo nths to < 6 months 1.33 4
6 mo nths to < 12 months 1.33 4
1 year to < 2 years 1.33 4
2 years to < 5 years 1.33 4
5 years to < 12 years 1.33 4
12 years to < 18 years 1.33 4
ADULTS and children 
with BW ≥ 75 kg100 mg 300 mg
Patients enrolled in each of the two treatm ent groups will receive a single oral dose of 
netupi tant per kg body  weight as described in Secti on 4.2Treatment Groups , 1 h 
(±10minutes) prior to start of emetogeni c (HEC or MEC) chem otherapy  on Day 1 and a 
single oral dose of palonosetron at the dosage of 20 µg/kg (maximum 1.5 mg), 
immediately (within 5 minutes) after netupitant, i.e., 1 h (± 10 minutes) prior to start of 
emetogeni c (HEC or MEC) chem otherapy  on Day  1. 
4.4 Packaging and Shipment
The invest igational products (netupitant vials and palonosetron vials) will be provi ded in 
sealed and appropri ately labeled study  kits. The netupi tant vials included in the kits will
have the same appearance for all the dosages; the different concentrations of the active 
pharmaceut ical ingredient (API) permit to have different netupi tant dosages by using the 
same vo lume, which is weight -based defined.
Packaging and labeling of the study drugs will be carried out in accordance with all 
applicable regulatory /legal requi rements by CSM Europe SA (previously B&C Group) 
(Belgium ).
Study  kit is inside of a carton box and contains 2 vials of palonosetron (up to 1.5 mg 
dosage), 1 vial netupi tant suspensi on and the ancillaries to be used for the collection and 
administration of the drugs. All the components of the study  kits are ident ifiable with 
different ly colored labels.
The procedure to be followed for the preparati on and administrati on of the drugs will be 
included in the Drug Manual provi ded to th e site staff before the start of the study  (also 
refer Section 4.8Rando mizat ion, Blinding and Assignment of Study  Drug ).
Page 262 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 54of 98
CONFIDENTIAL
The study  kits will be deliv ered either to a designated person at the site’s Pharmacy or 
directly to the Invest igator or designated staff, as applicable.
4.5 Storage
The study  drug will be delivered and stored at room temperature (below 25°C), in a 
secure area with limited access and protected from direct light. At the study  site, the 
designated responsible person for storage of the invest igational product (the site 
pharmacist or the Invest igator or a designee) shoul d also make sure that the drugs are 
kept separately from the other medications available on site and in no circumstance 
shoul d be mixed up wi th any other m edicat ions used at the trial site.
4.6 Drug Depots
The study  drugs ki ts will  be shipped from the central  depot to ei ther local drug depots, or 
directly to the study sites, as app licable. 
4.7 Accountability
Once the kits are received at the study  site, the pharmacist or designated responsible 
person will sign a drug recei pt form. Adequate records of the receipt, dispensat ion and 
return of study  drugs must be maintained throughout the study . Used study  drug ki ts will 
be retained unt il the drug accountabilit y has been checked by a designated monitor; a 
peel-off porti on of the study  drug label will also be affixed to th e drug preparation form 
as an additional accountabilit y measure in case internal policies requi re immediate 
disposal of the vials. Unused study  drug kits remaining at invest igational sites at the end 
of the study  will be returned to the drug depots for destructi on or will be destroyed at the 
sites as applicable. At the end of the study , delivery  records will have to be reconciled 
with those of used and returned stocks. Any discrepancy will have to be accounted for. 
Destruction of unused medicat ion will be documented in writing according to FDA IND 
regul ation 21CFR312.59, ICH Good Clinical Practice (G CP) and the drug depot Standard 
Operating Procedures (SOPs). Any destructi on of  remaining study  drugs material is to be 
first approved in writ ing by the study  Sponsor. 
4.8 Randomization, Blinding and Assignment of Study Drug
Randomization will be used to avoid bias in assigning patients to treatm ent and to 
increase the likelihood that known and unknown patient attributes are evenly balanced 
across treatment groups.
A computer -generated list of the kit numbers (“packaging list”) will be prepared by the 
Contract Research Organizat ion (CRO) to allow for blinding of the two treatm ent groups.
Sealed cartons (kits) containing the study  drugs will be prepared according to this 
packaging list. An appropriate amount of treatment kits will be supplied to the designated 
person at the invest igational sites at the beginning of the study , with further re-supplies 
scheduled once the number of available treatm ent kits decrease to a pre-set thresho ld at 
each site. Kits are indist inguishable, i.e., the netupitant vials contained in the kits have the 
same appearance for all the dosages; the different concentrati ons of the API permi t to 
Page 263 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 55of 98
CONFIDENTIAL
have different netupi tant dosages by using the same volume, which is weight-based 
defined.
The computer -generated patient randomizat ion list(s) will be prepared by the CRO to 
allow for random  treatm ent allocation where/when a random  treatm ent allocation is 
foreseen. The Interactive Web Response System (IWRS) provi der and a designated 
person at Helsinn will retain master copies of the packaging and patient rando mizat ion 
lists in a secure fashion to maintain the blind. 
Sponsor project team  members and members of the Invest igator’s team  will not have 
access to the lists. Patients will enter the study according to the design described in 
Secti on 3.1Study  Design and in Appendix 1.
Randomization/treatment assignmen t of eligible patients will be done using IWRS 
integrated wi th EDC system . Pati ents will be registered in the EDC at screening visit, and 
patient ident ificat ion number will be autom atically assigned by the system . Once a 
patient fulfills the inclusio n and exclusi on criteria, at Day  1 (Visi t 2) the Investi gator will 
ask for randomizat ion/treatment assignment through the EDC. The pat ient’s date of birth, 
the emetogenici ty and the schedule of the chem otherapy (all the inform ation is necessar y 
for ident ifying the patient’s strata) and the body  weight (necessary to establish the total 
dosages of netupi tant and palonosetron to be administered) are taken into considerat ion. 
These and other demographic data are stored in the IWRS module, together with the 
assigned t reatment.
The IWRS will assign the treatm ent to be administered to the patient through a static 
central  blocked randomizat ion for pati ents to be randomized and treated in a double -blind 
fashio n. The IWRS will assign the treatm ent to be administered to the patient in the 
youngest age classes (all age classes < 12 months) according to the study  design, i.e. the 
lowest netupitant dose(s) will be assigned and evaluated before escalat ing to the 
subsequent netupitant dose groups . 
Using the assigned dosage and th e patient’s weight, IWRS will customize pat ient-specific 
instructi ons for study  drug preparat ion and send them to designated person at the study 
site. 
The designated person at site will prepare the study drug following the instructi ons 
provi ded by the IWR S.
The IWRS will be open for randomizat ion / treatment assignment only for the 
age-class(es) that are allowed to include patients, according to the design and to the 
DSMB decisio ns. The IWRS will be closed for each age class once the relevant number 
of enrolled patients reached the planned target number of patients. 
4.8.1 Emergency Unblinding Procedure
As all pat ients will be treated wi th netupi tant, i t is unlikely that knowledge of the specific 
doses administered to an individual patient will provi de sufficient additional informat ion 
to the Invest igator to warrant breaking the blind for the patient. 
Page 264 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 56of 98
CONFIDENTIAL
However, if the Investi gator considers it essenti al to know the dose of netupi tant 
administered in order to adequately respond to a medical emergency, the Investi gator can 
obtain the treatm ent assignment of an individual patient through the IWRS. If possible, 
the Invest igator should discuss with the CRO Medi cal Moni tor whether unblinding is 
essent ial prior to contacting IWRS for the unblinding of the patient’s treatm ent 
assignment.
In case of unblinding, the Sponsor and CRO will be notified in a blinded fashio n 
immediately through an autom atic communication of the IWRS. Moreover, the 
Invest igator shoul d notify t he CRO Medical Moni tor and the Sponsor Drug Safety wi thin
24 h of the performed emergency  unblinding.
If the blind is broken for an individual pat ient, the Invest igator m ust record the f ollowing 
inform ation in the patient’s source documents:
-The date and time the blind was broken.
-The reason the blind was broken .
In case of unblinding by the Invest igator, the patient will be withdrawn fro m the study . 
If the blind is broken by the Sponsor (via IWRS) for pharmacovigilance reporting 
purposes in case of a suspected unexpected serious adverse react ion (SUSAR), the blind 
will be maintained for all other persons involved in this study . The patient will not be
withdrawn from the study  in case of unblinding by the Sponsor’s Drug Safet y Unit for 
pharmacovigilance reporting purposes. 
Any unblinding will be performed through IWRS (24-h coverage), and the unblinding 
procedure is described in detail in the IWRS instruction manual that will be provided 
separately . For the DSMB the unblinding process is described in the DSMB charter.
4.9 Over -dosage
In the unlikely event of  overdose, the pati ent should be managed wit h supportive care. In 
case of symptomat ic overdose, conservat ive management of signs and symptom s is 
advised. No case of over-dosage has been reported with netupi tant or palonosetron to 
date. No antidote for palonosetron or netupitant overdose is known.
4.10 Prior and Concomitant Medications
Inform ation on priorand concomitant medications will be collected beginning 14 days 
prior to Day  1 up to the fo llow-up visi t (Day  14 [+3]). 
4.10.1 Prior and Concomitant Treatments for the Prevention of Nausea and 
Vomiting or with Potential Antiemetic Effect
The use of any medicati on for the prevent ion of nausea and vomiting or the use of any 
medicat ion with potenti al antiemetic effects within the 24 h prior to the start of 
emetogeni c chem otherapy or during the 120 h after the start of emetogeni c chem otherapy 
is prohibited. For patients undergoing multiday emetogeni c chem otherapy, prevent ive 
antiemetic medication can be administered starting from > 24 h after start of  emetogeni c 
chemotherapy (HEC or MEC) on Day 1. The antiemet ic treatm ent shall be administered 
Page 265 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 57of 98
CONFIDENTIAL
as per local pract ice; however any further administrati on of netupi tant or pal onosetron is 
prohibited.
The list of prohibited medicat ions includes, but is not limited to:
-NK1-receptor antagonists (e.g., aprepitant or any  other new drug of this class); 
- 5 -HT3receptor antagonist s (e.g., ondansetron, granisetron, dolasetron, 
tropi setron, ramosetron);
-Benzamides (e.g., metoclopramide, alizapride);
-Phenothi azines (e.g., prochlorperazine, prom ethazine, perphenazine, 
fluphenazine, chlorpromazine, theithylperazine);
-Benzodi azepines initiated 48 h prior to study  drug administration or expected to 
be received within 120 h following initiation of chemotherapy, except for single 
doses of midazo lam, temazepam  or tri azolam;
-Buty rophenones (e.g., droperido l, haloperi dol);
-Anticholinergics (e.g., scopolamine, with the except ion of inhaled 
anticholinergics for respiratory disorders e.g., ipratropium bromide);
-Antihistamines (e.g., diphenhydramine, cycliz ine, hydroxy zine, 
chlorphenhyramine, dimenhydrinate, meclizine);
-Dom peridone; 
-Mirtazapine; 
- O lanzapine; 
-Prescribed cannabino ides (e.g., tetrahydrocannabinol, nabilo ne);
-Over the Counter (OTC) antiemetics, OTC cold or OTC allergy medicat ions;
-Herbal preparations containing ephedra or ginger.
The intake of palo nosetron is not permitted wi thin 1 wee k prior to administrati on of  study 
drug. 
The start of any systemic corticosteroi d therapy  within 72 h prior to study drug 
administration or the administration of a corticosteroid as part of the chem otherapy 
regimen is not permitted. 
The fo llowing exceptions are allowed:
-Patients who are receiving chroni c (> 72 h), daily steroi d therapy can be enrolled, 
provi ded the steroi d dose i s not > 0.14 m g/kg (up to 10 m g) of  predniso ne daily  or 
equivalent.
-For supportive care, patients will be permi tted to receive a single dose of 
corticosteroi d during the 72 h prior to study drug administration (but not < 12 h 
prior to study  drug administrati on) provi ded i t is less than the equivalent of 20 mg 
of prednisone. 
Rescue medicat ion for treatm ent of nausea and vomi ting is permi tted after the start of 
emetogeni c chem otherapy  administrati on; however any further administration of 
netupi tant or pal onosetron i s prohibi ted; use of metocl opramide is not permi tted as rescue 
medicat ion (see Sect ion 4.11 Rescue Medicat ion).
Page 266 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 58of 98
CONFIDENTIAL
4.10.2 Prior and Concomitant Cancer Chemotherapy and Radiotherapy
Patients must be scheduled to receive a course of HEC or MEC, administered on Day 1 
only or on multiple Days, either alone or in combinat ion with other chemotherapeut ic 
agents (see Appendix 2). For consistency of interpretation, “mult iple days” schedule 
woul d include regimens with additional HEC/MEC given between Day 1 and Day 6 
(within 120 hours from the start of first HEC/MEC administration on Day  1). 
Any low emetogenic chemotherapy  (LEC) agent or minimally  emetogenic agent given, as 
part of the aforem entioned chemotherapy regimens using HEC or MEC, i s allowed at any 
time during the study  and does not have any impact on the time of study drugs 
administration.
Total  body irradiati on, total  nodal irradiat ion, upper abdom en radi otherapy , half or upper 
body  irradiati on, radi otherapy of  the cranium , crani ospinal regi ons, head and neck, lower 
thorax region or the pelvis within 1 week prior to study entry  (Day 1) or within 120 h 
after study  drug administrati on on Day  1 are not permitted. 
4.10.3 Other Prior and Concomitant Medications
All medicat ions used within 14 days prior to Day 1, or administered during the study  as 
clinically indicated, are to be recorded on the appropri ate electroni c case report form 
(eCRF) pages. Prophylacti c infusio n of saline solution in order to prevent toxi c reacti ons 
related to chem otherapy is to be recorded. Inf usion of blood products has to be recorded. 
All medicat ions administered in relation to diagnostic procedures (e.g., anesthet ics, or 
antibiotics) are to be recorded.
According to protocol exclusio n criterion #11, any invest igational drug taken within 
90days prior to Day 1 for patients aged < 6 years, or any invest igational drug within 
30days prior to Day  1 for pati ents aged ≥ 6 years, or through the entire study  period are 
not allowed. For this purpose “Any invest igational drug" has to be intended as a 
medicat ion with no marketing authorization granted for any  age class and any indicat ion.
Based on exclusi on criteria #13 and 14, the intake of any drugs or substances known to 
be strong or m oderate inhibi tors of  CYP3A4 and CYP2D6 enzymes, including any  of the 
narrow therapeutic range CYP3A4 substrates, within 1 week prior to Day  1 or use of such 
medicat ions during the overall study  period (until Visit 5 inclusive) is not permitted 
(Appendix 4).
Based on excl usion criterion #15, the intake of  drugs or substances known to be inducers 
of CYP3A4 enzymes within 4 weeks prior to th e dosing day or use of such medicat ions
during the overall study  period (until Visit 5 inclusive) is not permitted (Appendix 4).
4.11 Rescue Medication
Rescue medicat ion shoul d be administered to alleviate established, refractory  or 
persi stent nausea or vomit ing and will be permitted on an as -needed basis.
Anti-emet ic medicat ions are not allowed as prevent ion of emesis, nor to increase the 
expected antiemetic effects of the study  drugs, except for pati ents receiving HEC or MEC 
beyo nd Day  1. 
Page 267 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 59of 98
CONFIDENTIAL
Rescue medication is defined as any medication taken to alleviate nausea or vomiting 
(i.e., with indicat ion nausea or vomit ing) during the period from start of emetogenic 
chemotherapy to 120 h later. The choice of rescue medication will be at the discre tion of 
the Invest igator. Invest igator must ensure that rescue medication is made available to 
patients whenever needed.
Use of palonosetron or netupitant other than study  drugs administration is not permitted.
Use of metoclopramide is not permitted as res cue medicat ion.
Page 268 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 60of 98
CONFIDENTIAL
5STUDY CONDUCT
5.1 General Instructions
During the course of the study , patients will undergo the following visits (see also the 
Flowchart ):
-Visit 1, screening (Day  -14 to -1 or Day -7 to -1 for patients aged < 2year), 
during which pat ients will be assessed for eligibilit y.
-Visit 2 (Day  1), during which pat ients fulfilling eligibilit y criteria will be enrolled, 
rando mized (as applicable), administered study  drugs and treated with 
chemotherapy; selected eligibilit y criteria will be re-checked at this visit prior to 
rando mizat ion/treatment assignment and treatment.
-Visit3 (Day 2, 3, 4 and/or 5, depending on PK sampling times), during which 
patients will have a PK sample(s) drawn and will be assessed for AEs and 
concomitant medicat ions.
-Visit 4 (Day 6, 7 or 8), final visit, during which a PK sample will be drawn, 
patient diary will be collected and patients will be assessed for AEs, conco mitant 
medicat ions, overall safet y and l aboratory  safet y data.
-Visit 5 (Day 14 [ +3]), follow-up visit or telephone contact for AEs and 
concomitant medicat ions.
5.2 Study Procedures by Time Point
5.2.1 Visit 1 (screening, Day -14 to -1 or Day -7 to -1 for patients aged < 2 
years)
If the Invest igator considers a patient to be potentially eligible for the study , the written 
inform ed consent/assent for participat ion in the study  must be obtained before any 
study -related procedures. The patient will be screened within 14 days (or within 7 days 
for patients aged < 2 years) prior to the first study drug administration and the following 
procedures will be performed/data collected during this visit:
-Inform ed consent signed by parent(s)/l egal guardian(s) of the pediatri c patient in 
compliance with the local laws and regulati ons. In addition signed children ’s 
assent form  according to l ocal requi rements. Informed consent/assent m ay also be 
collected before Visit 1.
-Eligibilit y criteria.
-Dem ographic data (gender, race, date of birth).
-Medical and surgical history  (including current cancer history  and naivet y to 
chemotherapy).
-History  of nausea and vo miting in previous chemo therapy  (if applicable).
-Prior and concomitant m edicat ions.
-Laboratory  tests, including: hematol ogy, serum  chemistry  and urinalysis. Urine 
samples will be obtained only if the patient is capable of providing a urine sample.
-Urine pregnancy  test (f or female pat ients having reached menarche only).
-Full physical examinat ion.
Page 269 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 61of 98
CONFIDENTIAL
-Vital signs (pulse rate, systolic and diastolic blood pressure), height/length, 
weight.
- 12 -lead ECG (single recording).
-AE recording.
-ECOG PS (assessed for patients aged ≥ 10 y ears).
-Instructi on to patient and to parent(s)/legal guardians of the pediatri c patient on 
how to fill in the pat ient diary. 
Based on the outcom e of the assessments, the Investi gator will be able to decide if the 
patient is eligible for the study .
5.2.2 Visit 2 (Day 1)
The fo llowing procedures will be performed/data collected:
-The patient will undergo pre-dose assessments, including confirmat ion of 
inclusio n and exclusi on criteria (local laboratory resul ts from an appropriately 
certified local laboratory  coul d be used at the discretion of Invest igator to evaluate 
patients’ eligibili ty; in case of ERT central  ECG report pending, the assessment of 
compliance with exclusio n criterion #21 could be made based on autom atic 
interpretati on of QTcB and QTcF resul ts by ECG machine at the discretion of 
Invest igator ).
-Urine pregnancy test (for female patients having reached menarche only; if 
screening visit is performed on Day -1, it is not necessary  to repeat the teston 
Day 1.).
-Concomitant medicat ions and AEs recording
-Weight 
-Treatment assignment / Randomizat ion through IWRS. 
After randomization/treatment assignment, the study  drug administrati on schedule is the 
following:
-Netupi tant will  be administered based on t he body  weight as a single oral  dose 1 h 
(± 10 minutes) pri or to s tart of  emetogeni c (HEC or MEC) chem otherapy on Day 
1. 
-Palonosetron will be administered orally immediately (within 5 minutes) after 
netupi tant, i.e., 1 h (± 10 minutes) prior to start of emetogeni c (HEC or MEC) 
chemotherapy on Day  1.
-Any LEC or minimally emetogenic agent given, as part of the aforementi oned 
chemotherapy regimens using HEC or MEC, is allowed at any time during the 
study  and does not have any impact on the time of study  drugs administration.
The date and the precise time (hh:mm) of the study drug administrati on must be recorded 
in the source records as well as on the relevant eCRF page for each medicat ion given. 
Inform ation on completeness of study drug administration must berecorded as well. The 
relevant tear-off labels from the study drugs kit will be attached to the drug 
administration form. 
Page 270 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 62of 98
CONFIDENTIAL
-PK sampling: a single bl ood sam ple will be collected from  each pati ent wi thin the 
time window fro m 2 to 8 h after netupi tant administration . Sam pling will take into 
account the time o f the 12-lead ECG and vital signs (see below).
-Vital signs (pulse rate, systolic and diastolic blood pressure) will be obtained 
4-6h after study  drugs administration, before PK sampling or at l east 30 minutes 
after PK sam pling.
-A 12-lead ECG (single recording) will be obtained 4-6 h after study  drugs 
administration, before PK sampling or at least 30 minutes after PK sampling.
-The diary  covering 120 h after start of  emetogeni c chem otherapy will be supplied 
to all pat ients. Pati ent or pati ent’s parents/l egal care hol ders have to record em etic 
episodes and use of any  rescue medicat ion. 
5.2.3 Visit 3 (Day 2, 3, 4 and/or 5 depending on the PK sampling times)
The fo llowing procedures will be performed/data coll ected:
-Concomitant medicat ions
-AEs recording
-PK sampling: a single blood sam ple will be collected fro m each pati ent wi thin the 
time window from 24-48 h after netupi tant administration . For pediatric patients 
≥ 5 years, an additional PK sample will be colle cted from each patient within the 
time window from 72 -96 h after netupitant administration.
-Review of patient diary  and instructi ons. During the visit, after the diary  has been 
reviewed, the patient will be asked to correct errors, omissio ns, or ambigui ties, if 
any.
5.2.4 Visit 4 (final visit, Day 6, 7 or 8 depending on PK sampling times)
The fo llowing procedures will be performed/data collected:
-Concomitant medicat ions
-Laboratory  evaluat ions (hematol ogy, serum chemistry  and urinalysis; pregnancy 
test [(for femal e patients having reached menarche only])
-Full physical examinat ion
-Vital signs (pulse rate, systolic and diastolic blood pressure; to be measured 
before PK sampling or at least 30 minutes after PK sampling)
- 12 -lead ECG (single recording), before PK sampli ng or at least 30 minutes after 
PK sampling.
-AEs recording
-Check and retrieval o f the com pleted patient diary  
-PK sampling: a single blood sam ple will be collected fro m each pati ent wi thin the 
time window from 120 to 168 h after netupi tant administrati on.
Page 271 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 63of 98
CONFIDENTIAL
5.2.5 Visit 5 (follow up visit, Day 14 [+3])
On Day 14 (+3) the following follow up procedures will be performed/data collected 
during a visit or via telephone contact:
-Concomitant medicat ions
-AEs recording.
5.3 Definition of Completion
A patient will be defined as “completed” if s/he completes the study  until Visit 5
(inclusive). 
5.4 Premature Discontinuation
Patients may discont inue the study  or may be withdrawn at any time for any of the 
following reasons:
-An AE that, in the opinion of the Invest igator, makes it unsafe for the patient to 
continue the study . In this case, the appropriate measures will be taken.
-Any clinically significant laboratory  abnorm alities that in the Invest igator’s 
opinio n endanger the patient.
-The patient’s safet y is affected by vio lation of inclusion or exclusio n criteria.
-The patient and/or the parent(s)/ legal guardi an(s) requests withdrawal from the 
study . 
-The Invest igator, for any reasons, terminates the entire study , or terminates the 
study  for this patient; or the attending physician requests that the patient be 
withdrawn for any  other m edical reasons.
-The patient is unwilling or unable to adhere to the study  requirements after 
rando mizat ion/enrollment, e.g., non -compliance. 
-Whenever the study blind is broken by the Investi gator, the patient will be 
autom atically withdrawn fro m the study . 
-The patient is lost to follow -up.
-The patient dies.
-The Sponsor or the Regulatory  Authori ties or the Ethics Committees, for any 
reason, terminates the ent ire study , or terminates the study  for that pa tient or study 
center.
In all cases where a patient is withdrawn from the study , CRO must be informed 
immediately , and the date and reason for withdrawal must be recorded on the eCRF and 
in the patient’s medical records. If more than one reason for withdrawal is recorded, the 
primary  reason must be given. 
If the pat ient is withdrawn due to an AE, including concomitant disease, full details o f the 
event and treatm ent must be recorded in the patient’s source docum ents and the eCRF. 
For non-serious AEs, the patient must be followed up unt il the cause of the event is 
established with follow-up informat ion recorded up to 14[+3] days post-dose. For SAEs, 
the patient must be followed up unt il the cause of the event is established and shoul d be 
followed up until they are completely resolved or until a stable condi tion has been 
Page 272 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 64of 98
CONFIDENTIAL
reached as no further improvement or change is expected according to conventional 
medical pract ice and according to the Invest igator’s judgment or un til the patient is lost to 
follow-up (see Section 7.1.3 Reporting of Adverse Events and Secti on 7.1.4.1Reporti ng 
of Serious Adverse Events ). 
If the pat ient is lost to f ollow up, all  attem pts to contact the pati ent shoul d be docum ented 
in the pat ient’s medical records. 
All patients included in the study will be administered study  drug (netupi tant and 
palonosetron) on Day 1 (Visi t 2); patients receiving the study  drug will be evaluated 
regardl ess of completion of all study  visits. An effort will be made to gather as much 
inform ation as possible. Every attem pt shoul d be made to perform a final evaluat ion 
(Visit 4 proce dures -see Flow Chart ) for any  patient who i s withdrawn from  the study  for 
any reason excluding withdrawal  of consent/assent. In addit ion, the Invest igator must try 
his/her best to contact the pati ent wi thin 14 to 17 days after the study  drug administrati on 
to assess safety  issues by collecting informat ion suggestive of AEs and conco mitant 
medicat ions. Withdrawn patients will not be replaced. If the study  is discont inued 
prem aturely , all study  materials (study  drug, etc.) must be returned to the Sponsor. A 
written statement fully docum enting the reasons for terminat ion will be provi ded to the 
Invest igators, the IEC/IRB, and Regulatory  Authori ty (as appropri ate to local 
regul ations).
Page 273 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 65of 98
CONFIDENTIAL
6METHODS OF ASSESSMEN T
6.1 Pharmacokinetic Assess ments
The PK profiles of netupi tant, its active metabo lites M1, M2, M3, and palonosetron will 
be evaluated in pediatric cancer patients according to a sparse sampling schedule and a 
popul ation PK approach.
A single blood sample will be collected from each patient in each of the following time 
windows:
Pediatric patients ≥ 5 years: from 2 to 8 h, from 24 to 48 h, from 72 to 96 h, and 
from 120 to 168 h after netupi tant administration .
Pediatric pati ents < 5 years: from 2 to 8 h, f rom 24 to 48 h, and from  120 to 168 h 
after netupi tant administration .
The actual  sampling times will  be recorded in the individual  source documents and in the 
eCRF, and will be used in PK calculat ion.
The nominal number of plasma samples collected from all patients from each of the two 
treatm ent groups will be 154. The expected total number of plasma samples collected 
from the two treatm ent groups will be 308. 
The vo lume of each bl ood sam ple will be 2.0 mL. For pati ent with body  weight <5.4 kg, 
the volum eof each blood sample will be limited to 1.0 mL [38].
Data modelling will be based on a previ ous populati on PK study in adults receiving oral 
NEPA administrati on (study  NETU -10-02 [26]). A two-compartm ent open model with 
first order absorption and eliminat ion with lag-time adequately described the netupitant 
and palonosetron plasma concentrati on-time profiles, whereas a one-compartment model 
best fit the metabolite M1 and M3 concentrati on data, and a three-compartm ent model 
described the metabo lite M2 data. 
If the same structural  models apply to the pediatric popul ation, the ty pical  values (TV) of 
the following structural  model parameters will be assessed for netupitant and 
palonosetron: 
-Ka: absorpti on rate constant for netupitant or formation rate constant for 
netupi tant m etaboli tes
-tlag: lag time
-Vi/F: apparent volume of compartment i, i.e., central  and peripheral 
compartment(s), for ext ravascular administration
-CL/F: apparent sy stemic clearance for extravascular administration
-Q/F: inter -compartm ental  clearance
F is the absolute oral bioavailabilit y for the parent compounds netupi tant and 
palonosetron. 
Different structural models could also be explored for netupitant, its metabolites, and 
palonosetron according to the findings of the present PK/PD study  in pediatri c patients 
after oral administration of netupi tant and palonosetron. The final model parameters will 
Page 274 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 66of 98
CONFIDENTIAL
reflect the model struct ure and include possible continuous or categori cal covariates that 
significant ly correl ate wi th PK parameters and explain inter -subject variabilit y.
Individual model-predicted PK parameter values will be estimated from the final 
popul ation pharmacokinet ic models, based on mean popul ation parameter values (ty pical 
values, TVs) and on the individual random  effect (ηi). From  final model parameters, 
individual plasma concentrati on-time profiles will be simulated and secondary PK 
param eters such as C max, tmax, AUC and t 1/2estimated by non -compartmental methods.
6.1.1 PK Sampling and Sample Handling
Blood samples will be collected for the determinat ion of netupi tant, netupi tant 
metabo lites, and pal onosetron concentrations. 
A total of 3 or 4 (only for pedi atric patients aged ≥ 5 years) bl ood sam ples (2.0 mL each;
for pati entswith body weight <5.4 kg, the vol ume of  each blood sam ple will  be 1.0 mL)
per patient will be taken according to the foreseen schedule.
The total number of data points from all patients will be 308. The total blood volume 
collected per patient will be approximately 3.0 to 8.0 m L.
In case of blood samples withdrawn from a central  access or via an indwelling catheter, 
the cannula will be rinsed after each sampling with sterile saline solution containing 
20IU/mL Na-heparin. At each sampling time, the first ca.1.0 mL of blood will be 
discarded to avoid contaminat ion of the sample with the Na-heparin solution. Then 
2.0mL blood (for patient swith body weight <5.4 kg, the volume of each blood sample 
will be 1.0 mL) will be collected into tubes containing K2-EDTA as anti coagul ant. Af ter 
collect ion, blood samples will be centrifuged immediately or stored, before 
centrifugation, in a refrigerator at +4 2°C or in a melting ice bath for a maximum of 
30min. Centrifugat ion will be done by a centrifuge to obtain plasma. 
Each plasma sample will be immediately divided into 4 aliquots (2 aliquots for patient s
with body weight <5.4 kg) in pre-labeled polypropylene tubes: 2 aliquots (1 aliquot for 
patientswith body  weight <5.4 kg) ≥130 μL each (sample and back-up sample) for the 
analysis of netupi tant and its metabolites (M1, M2, M3), 2 aliquots (1 aliquot f or pati ents
with body weight <5.4 kg) of ≥ 250 μL each (sample and back -up sample, for patient s
with body weight <5.4 kg no back-up samples are to be obtained ) for the analysis of 
palonosetron. Pl asma samples will be stored frozen at -20° C or -70°C until analysis.
Further instructions on collection, handling, labeling, storage and shipment of PK 
samp les are reported in the Laboratory  manual .
6.1.2 Analytical Procedures
Netupi tant, netupi tant metaboli tes M1, M2 and M3, and pal onosetron concentrati ons will 
be determined in plasma samples at an accredited bioanalyt ical laboratory . 
Validated liquid chromatogra phy with tandem mass spectrom etry (LC-MS/MS) methods 
with appropri ate lower limit s of quantificat ion (LLOQ) will be used. 
Page 275 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 67of 98
CONFIDENTIAL
The method for the determinat ion of netupi tant and its metabo lites requi res a sample 
volume of 50 µL and has a LLOQ of 2 ng/mL for each analy te. For palonosetron 
determinat ion, the method requires a sample volume of 100 µL and the LLOQ is 
50pg/mL.
Details of determinat ion of netupi tant, netupitant metabo lites and palonosetron in huma n 
plasma of this clinical study  will be included in the bioanalyt ical study  plan. Analyses 
will be performed according to the general principles of “OECD Good Laboratory 
Practi ces for testing of chemicals" C(81)30(Final ). The bioanalyt ical report will be 
appended to the CSR.
6.2 Efficacy Assessments
Efficacy assessments will be collected through a paper diary , which will be used to 
record em etic episodes and use o f rescue medicat ion. An emet ic episode is defined as one 
or m ore continuous vomi ts (expulsi on of stomach contents through the mouth) or retches 
(an attem pt to vomit that is not productive of stomach contents). Regurgitation (defined 
as the sudden effortless return of small volumes of gastri c contents into the pharynx and 
mouth–typically after breast feeding or bottl e feeding) is a physi ological event and must 
not be considered as an emetic episode (for patients up to 12 months of age).Patients, 
parents/guardians or caregivers shoul d complete the diaries. Instructi ons on how to 
compile the paper diary will be given at the Screening Visi t (Visit 1). Paper di ary will be 
distributed at Day  1 (Vi sit 2) and will be collected at Final Visit (Visit 4). 
6.2.1 Primary Endpoint
PK/PD relationship between netupi tant exposure (AUC, Cmax) and antiemetic efficacy in 
the delayed phase after a single oral netupi tant administration, concomitant ly with oral 
palonosetron, in pediatri c cancer patients receiving HEC or MEC treatm ents. Efficac y 
param eter to be used in thecorrel ation is the proporti on of patients with CR (i.e., no 
emetic episodes and no rescue medicat ion) during the del ayed phase (> 24 -120 h after the 
start of chemotherapy on Day 1). 
6.2.2 Secondary Endpoints
-Pharmacokinet ic (PK) endpo ints: 
AUC, Cmax, tmax andt1/2of netupi tant, netupitant metabolites M1, M2, M3, and 
palonosetron.
-Pharmacodynamic (PD) endpoints: 
proporti on of patients with complete response (CR, i.e., no emet ic episodes and 
no rescue medicat ion) during the delayed (> 24 -120 h), acute (0 -24 h) , and overall 
phases (0 -120 h) after start of chemotherapy  administrati on on Day  1.
proporti on of patients with no emetic episodes during the delayed (> 24-120 h), 
acute (0-24 h), and overall phases (0-120 h) after start of chemotherap y 
administration on D ay 1.
Page 276 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 68of 98
CONFIDENTIAL
proporti on of  patients wi th no rescue medication during the delayed (> 24 -120 h), 
acute (0-24 h), and overall phases (0-120 h) after start of chemotherap y 
administration on Day  1.
Page 277 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 69of 98
CONFIDENTIAL
6.3 Safety Assessments
Safety assessments will consist of full physical  examinat ion (PE) and clinical laboratory 
tests (serum chemistry , hematol ogy, urinalysis): these assessments will be performed at 
screening and at final visit (Visit 4). Moreover, vital signs measurements (pulse rate, 
systolic and diastolic blood pressure) and 12 -lead ECGs (single recordings) will be 
obtained at screening, on Day  1 at 4 -6 h after study drug administration, and at final visit. 
Adverse events (AEs) will be monitored throughout the study .
6.3.1 Physical Examination
A full physical examinat ion will be performed at Vi sit 1 (screening) and Visi t 4 (Day 6, 7 
or 8). This evaluat ion will include an examinat ion of general appearance, head, eyes, 
ears, nose, throat, skin, neck, lungs, cardi ovascul ar, breast, lymph nodes, abdo men, 
musculoskeletal and neuro logical. Inform ation about the physical examinat ion will be 
recorded in the source docum entati on at the site and in the eCRF. Significant 
findings/illnesses, discovered after the first study drug administrati on and which meet the 
definit ion of an AE, will also be recorded in the eCRF.
6.3.2 Vital Signs
Vital signs assessments will include: pulse rate, systolic and diastolic blood pressure, 
height/l ength (only at Visit 1, screening), and body weight (at Visit 1 and Visit 2). Pul se 
rate, systolic and diastolic blood pressure will be measured after the patient has been in 
the sitting or lying position for at least 5 minutes at Visit 1 (screening), Visit 2 (4-6 h 
after study  drugs administration; Day  1) and Visi t 4 (Final  visit, Day  6, 7 or 8). 
Vital signs shall be measured before PK sampling or at least 30 minutes after PK 
sampling.
6.3.3 12-lead ECG
Twelve -lead ECGs (single recording) will be recorded for each patient at Visit 1 
(screening), Visit 2 at 4-6 h after study  drugs administration, and Visit 4 (Day  6, 7 or 8, 
final visit). A digitally recorded ECG will be transmi tted from the study site to a cen tral 
reading facilit y, where ECG interpretati ons will be timely performed by a cardi ologist (in 
case cardi ologist’s report is pending, the assessment of compliance with exclusion 
criterion #21 coul d be made based on autom atic interpretati on of  QTcB and QTcF resul ts 
by ECG machine at the discret ion of Invest igator). ECG interpretati on scheme will 
include the analysis of the morphology, rhythm, conducti on, ST segm ent, PR, QRS, QT 
and QTc intervals, T waves, U waves and the presence or absence of any pathol ogical 
changes. The investigator will receive more detailed inform ation regarding the ECG 
recording and assessment procedures in a separate manual.
After review of the resul ts received from  the central  reading facilit y, the invest igator must 
sign and date each ECG report.
ECGs shall be obtained before PK sampling or at least 30 minutes after PK sampling.
Page 278 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 70of 98
CONFIDENTIAL
6.3.4 Clinical Laboratory Tests
The fo llowing param eters will  be assessed at V isit 1 (screening) and Visit 4 (final visit):
a)Hem atology: hematocri t, hemoglobin, erythrocytes (RBC), platelets, leukocytes 
(WBC), neutrophils, lymphocy tes, basophils, eosinophils, monocy tes.
b)Blood Chemistry: urea, creatinine/eGFR, total bilirubin, alkaline phosphatase 
(ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), 
sodium, potassi um, albumin, total  protein, bl ood glucose and total  creatine kinase 
(CK).
c)Urinalysis: protein, glucose, WBC, RBC, and bacteria.
Female patients having reached menarche will have to un dergo a urine pregnancy test at 
screening and on Day  1, as well as a blood pregnancy test on Visit 4 (final visit) as part of 
the clinical laboratory  assessments. 
All blood and urine samples collected at Visit 1 and Visit 4 will be sent to a central 
laboratory for analysis. Local  laboratory  results obtained from an appropri ately certified 
local laboratory  within the screening peri od coul d be used to support eli gibili ty criteria at 
the discret ion of Invest igator. Only the confirmat ion of eligibilit y will be recorded in the 
eCRF as local laboratory  values will not be entered into the eCRF.
After review o f the resul ts received from  the central  laboratory , the invest igator must sig n 
and date each laboratory  report. The laboratory will provide norm al reference ranges for 
the laboratory  results report and will flag all abnorm al values. The invest igator will 
consider the values outsi de the normal range and repeat the test, if needed. In case 
clinically significant laboratory  abnorm alities are assessed by the Invest igator, the 
etiology of the abn ormality shoul d be ident ified and the diagnosis shoul d be recorded as 
an AE. Otherwi se, if the eti ology cannot be identified, the laboratory  abnorm ality as such 
shoul d be recorded as AE. 
Clinically significant laboratory  abnormali ties (including those values ≥ grade 3 severi ty) 
detected after screening, if not justified by an underlying disease already recorded in the 
medical history , are to be recorded as AEs. 
Page 279 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 71of 98
CONFIDENTIAL
7ADVERSE EVENTS
7.1 Method of Assessment
7.1.1 Definition of Adverse Events
Adverse Event (AE)
As defined by the current ICH Guideline for Good Clinical Pract ice [27] an Adverse 
Event (AE) i s:
Any untoward medical occurrence in a patient or clinical invest igation subject  
administered a pharm aceutical product and which does not necessarily have to have a 
causal relationship with this treatm ent. An AE can therefore be any unfavorabl e and 
unintended sign (including an abnormal laboratory  finding), symptom , or disease 
temporally  associated with the use of a medicinal (investi gational) product, whether or 
not c onsidered rel ated to the m edicinal (investigational) product.
Within the scope of this study , such untoward medical occurrences woul d be considered 
as “AEs” even if the subject was not administered the study  drugs but the subject (and/or 
subject’s parent/g uardi an, as applicable) had already  signed the Inform ed Consent/Assent  
Form .
This defini tion includes intercurrent illnesses or injuries, exacerbat ion of pre-exist ing 
condi tions, and adverse events occurring as a resul t of drug withdrawal , abuse, 
medicat ion errors, misuse or overdose. Adverse events observed during all periods of a 
clinical trial are to be recorded, including adverse events occurring during a period 
without tri al medicati on. 
Planned surgical interventi ons or planned hospi talizat ions schedu led prior to the 
Inform ed Consent but perform ed during the study  should not be considered (serious) 
AEs. 
Signs and symptom s considered as lack of efficacy (nausea and vomiting) and occurring 
during the study  up to 5 day s after the study  drugs administrati on, will not be recorded on 
the AEs section of the eCRF, except on the conditi on that, in the investigator’s opinio n, 
nausea and vomiting are caused by any reason different from lack of efficacy of study 
drug or meet the definit ion of serious AE.
Serious A dverse Event (SAE)
Aserious adverse event is any event that suggests a significant hazard, contraindicat ion, 
side effect, or precaution, whether or not it is consi dered to be associated with the study 
product. A SAE is an AE that meets any  of the f ollowin g criteria:
-Results in death. This includes any death that occurs during the conduct of a 
clinical study , including deaths that appear to be com pletely unrelated to the study 
drugs (e.g., car accident).
-Is life-threatening. This includes any AE during whic h the subject is, in the view 
of the invest igator, at immediate risk of death from the event as it occurs. This 
Page 280 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 72of 98
CONFIDENTIAL
definit ion does not include events that may have caused death if they had occurred 
in a more severe form .
-Requi res inpat ient hospi talizat ion or prolongat ion of exist ing hospi talizati on
-Results in persistent or significant disabilit y or incapaci ty
-Is a congenital ano maly or bi rth defect
-Other medical events that based upon appropri ate medical judgment are thought 
to jeopardi ze the pati ent and/or re quire medical or surgi cal interventi on to prevent 
one of the outcomes defining a SAE.
Unexpected Adverse Event
AnUnexpected Adverse Event is any experience not previously reported (in nature, 
severit y or incidence) in the current IB for oral NEPA FDC [16].
Expedited Adverse Event Reporti ng
Any serious and unexpected AE that the Invest igator or the Sponsor considers to be at 
least possibly related to study  drug issubject to expedited reporting to the appropriate 
Health Authori ties. Events for whi ch causali ty is unknown/unassessable or unreported by 
the Invest igator are considered to be possibly related.
Non-serious Adverse Events
Non-serious adverse events shoul d be included in tabulati ons in the end-of-study  and do 
not need to be submitted separately .
Preexist ing Condit ion
A pre-exist ing condi tion is one that is present at the start of the study . A pre-exist ing 
condi tion shoul d be recorded as an AE if the frequenc y, intensity, or th e character of the 
condi tion worsens during the study  period. 
7.1.2 Classification of Adverse Events
The Investigator will classify AEs based on their severit y and relat ionship to IMP. 
Every  effort must be made by the Invest igator to categorize each AE according to its 
severit y (see Section 7.1.2.1 Severit y) and its relationship (see Section 7.1.2.2
Relationship to Invest igational Medicinal Product ).
7.1.2.1 Severity
The severit y of an AE will be rated by the Invest igator according to the descriptions and 
grading scales of the Commo n Termino logy Criteria for Adverse Events (CTCAE) (for 
details please refer to the integral  document Termino logy Criteria for Adverse Event s 
(CTCAE, Versi on 4.0, published: May 28, 2009 [v4.03: June 14, 2010]); U.S. 
Departm ent of Health and Human Services, National Institutes of Health, National 
Cancer Inst itute) [28], as summarized below:
Page 281 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 73of 98
CONFIDENTIAL
Severit y of AE according to CTC Grading Scale and related Guideline
Grade 1 Mild; asymptom atic or m ild symptom s; clinical or di agnostic observat ions 
only; intervent ion not indicated;
Grade 2 Moderate; minimal, local or noninvasive intervent ion indicated; limit ing 
age-appropriate instrumental Act ivities of Daily  Living (ADL)*;
Grade 3 Severe or medically significant but not immediately life-threatening ; 
hospi talizati on or prolongati on of hospi talizat ion indicated; disabling ; 
limit ing self -care ADL**;
Grade 4 Life-threatening consequences; urgent intervention indicated;
Grade 5 Death rel ated to AE.
(*) Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, managing 
money, etc. 
(**) Self -care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not 
bedridden.
7.1.2.2 Relationship to Investigational Medicinal Product
For this trial, an AE cause and effect relationship to th e study  drug will be classified by 
the Invest igator as reported hereafter.
Scale Definition
Definitely Related The evidence is compelling that the study  drug caused the adverse event. There is 
a clear temporal relationship of the event to the study  drug; the event is consistent 
with a known pattern of drug (or drug class) effects; the event cannot be explained 
by concurrent disease or other drugs or chemicals; the event diminished upon 
cessation of study  drug exposure or reduction in dose; the event worsened or 
recurred upo n unintentio nal re -exposure to the study  drug (intentional rechallenge 
for the purpose of assigning causality should not be performed).
Probably Related It is more likely that the event is due to the study drug than due to other etiologies, 
an alternative explanation is unlikely. There is a reasonable temporal relationship 
of the event to the study drug; the event may be consistent with a known pattern of 
drug (or drug class) effects; the drug seems more likely than other etiologies to 
cause the effect; the event diminished upon cessation of study drug exposure or 
reductio n in dose.
Possibly Related It is equally likely  that the event is due to the study drug as it is due to other 
etiologies. There is a reasonable temporal relatio nship of the event to the study 
drug; follows a known or expected response pattern of the suspected drug but 
could also have been easily produced by a number of other etiologies.
Unlikely  related It is more likely that the event is due to other etiologies than due to the study drug. 
The event could have been reasonably  related to patient's underlying diseases or 
concomitant treatments and/o r the temporal relationship is doubtful between the 
study drug and the suspected adverse event.
It the tempo ral relationship of the event to  the study drug is reasonable, but there 
are impo rtant confounding factors/reasonably convincing alternative explanatio ns, 
causality is considered unlikely.
Page 282 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 74of 98
CONFIDENTIAL
Scale Definition
Not related The study drug almost certainly (or certainly) did not cause the event. Sufficien t 
information exists to indicate that the etiology is unrelated to the study drug, e.g., 
the event is more likely related to patient's underlying diseases or concomitant 
treatments and/o r there is no temporal relationship between the study  drug and the 
suspected adverse event, e.g., the event occurred before the study drug was 
administrated.
Unassessable The data are insufficient or contradictory to make a meaningful medical 
assessment.
7.1.3 Reporting of Adverse Events
AE reporting has to be in accordance with the ICH E6 Guidance on GCP and ICH E2A 
Guidance on Clinical Safet y Management. [27, 29]
During the course of the study , all AEs (including SAEs), irrespect ive of the relatedness
to the study  drugs, will be recorded in detail in the source records and transcribed onto 
the AEs pages of the eCRF. During each m onitoring visi t, the si te monitor will review all 
AEs and perform Source Data Verificat ion (SDV). The investigator will be respons ible 
for ensuring that the correct inform ation concerning all AEs is entered on the appropri ate 
eCRF pages.
The reporting period for AEs is the period starti ng from the time of Inform ed Consent  
Form signature and lasting until Visit 5 or up to 14[+3] day s post-dose. All non-resolved 
AEs (including SAEs) bey ond this date will be documented on the eCRF as “ongo ing”.
7.1.4 Reporting of Serious Adverse Events
All SAEs occurring from the time of signing of the Inf ormed Consent Form /Assent until 
14[+3] days post-dose must be reported immediately to the CRO Pharmacovigilance 
e-mail address or sent by  fax (see Sect ion General Informat ion). 
The investigator or desi gnated study coordinator must transmi t the completed SAE Form 
to the CR O wi thin 24 h of observati on or notificati on of a SA E. All of  these events must  
also be recorded on the appropriate eCRF pages.
It is the responsibili ty of the Invest igator to inform his or her local Institutional Review 
Board (IRB)/Ethics Committee (EC) about SAEs according to the local IRB/EC 
requi rements. It is the responsibilit y of the Sponsor (or Sponsor’s designee) to submit  
applicable SAE Reports to the Competent Authori ties. Reporti ng of suspected 
unexpected serious adverse reacti ons (SUSARs) to therelevant IRB/EC, in accordance 
with the EU Clinical Trial  Directive 2001/20/EC, the US Code of Federal Regulat ions 
313.32 and ICH E6 Guidance on GCP and ICH E2A Guidance on Clinical Safet y 
Management and all the applicable country regul ations, will also be the responsibili ty of 
the Sponsor (or Sponsor’s designee). [27, 29]
A safety  contact sheet will be provided to th e investigator and will be maintained in the 
investigator file at the site. Refer to the instructions and defini tions for completing the 
SAE Form and for submitt ing all SAEs to the CRO.
Page 283 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 75of 98
CONFIDENTIAL
7.1.4.1 Follow -up of Serious Adverse Events
For safet y monitoring purpose, SAEs will be followed up by the Invest igator until they 
are completely resolved or until a stable conditi on has been reached as no further 
improvement or change is expected according to convent ional medical pract ice and 
according to the Investi gator’s judgment or until the patient is lost to follow-up. When 
the invest igational site receives any inform ation about a serious adverse event which 
changes or adds informat ion to the ini tial investi gational SAE form , the si tewill fill out a 
new invest igational SAE form, tick the”follow-up” box and send the form via e-mail or 
fax within 24 h to the CRO, especially if this new informat ion has an effect on the 
seriousness, relatedness or expectedness of an adverse event.
7.1.4.2 Adverse Events of Special Interest
Speci al attenti on will be paid to QT prol ongat ion and consti pation, in particular to severe 
forms of constipation (CTCAE grade 3 or 4 [28]). In such cases, an accurate follow up 
will be performed by  the Sponsor. 
7.1.5 Pregnancy Report
In the unlikely eventualit y that a patient becom es pregnant during the trial, the 
Invest igator will be requested to complete the Pregnancy Report Form and any relevant 
docum ent. They  must be forwarded to the CRO pharm acovigilance e -mail address or sent 
by fax (see Section General Information) within 24 h of becoming aware of the 
pregnancy. Even though pregnancy is not considered as SAE itself, pregnancy has to be 
reported within the t imelines defined for SAE.
Pregnant patients, as well as partners of male patients who beco me pregnant during the 
study , will be foll owed by  the Invest igator and CRO / Sponsor until the fetus / newborn is 
delivered. Reports of Pregnancy Outcom e will be sent by the sites directly to Helsinn 
Corporate Drug Safet y. The pat ient’s/partner’s primary care physician (or obstetri cian) 
will be requested by the Invest igator to provide further informat ion on the pregnancy 
outcom e and to complete the Pregnancy Information Letter. If pregnancy occurs in a 
female patient between the screening and randomizat ion phase, that patient will be 
removed from  the study .
Page 284 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 76of 98
CONFIDENTIAL
8STATISTICS
This section summarizes the statistical principles and methods planned to analyze the 
data for this clinical study . The reference document is the ICH Topi c E9 Statistical 
Principles for Clinical Trials: Note for Guidance on Statist ical Principles in Clinical 
Trials [30].
Further details of the stati stical analyses and data presentations to be used in reporting the 
study  will be provi ded in the Statistical Analysis Plan (SAP), which will be finalized 
prior to data analysis.
8.1 Sample Size Determination
A total of 92 pediatri c patients (i.e., 46 for each treatm ent group) will be enrolled in the 
study . 
For each age class used for stratification, a sample size was computed. Each age class is 
powered to target a 95% confidence interval within 60% and 140% of the geometric 
mean est imate of clearance with at le ast 80% power.
The sample size was computed for the following age classes: Birth-<1 month, 
1<3months, 3-<6 months, 6-<12 months, 1-<2 years, 2-<5 years, 5-<12 years, 
12-<18years.
Variability of clearance in each pediatri c age class was estimated based on the same 
model used to determine the dose to be administered, which is:
Log(CL/F)p = log(CL/F)a + ADE∗log(BWp/70)
where (CL/F)p and (CL/F)a are the systemic clearances in pediatri c patients and adults, 
respectively , BW p is the body  weight of children and ADE is an age -dependent exponent 
considered constant within each age class. 
Variance o f log (CL/F)p was then calculated as:
ADE2 * Vari ance (l og (BWp))
considering log (CL/F)a as a constant term.
Variance (log (BWp)) was obtained from published data in Fryar et al 2012 [31], where
mean values in each age class and related standard errors were available.
Based on these data, the variance o f log wei ght was obtained as:
Variance (BWp) = standard error2 * N
and
Variance (l og BWp) ≈ Variance (BWp) / Mean2
(i.e., no assumpt ion on the st atistical distribution was made); 
Page 285 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 77of 98
CONFIDENTIAL
The table below reports the values as selected from published data in Fryar et al 2012
[31] and the further elaboration
Age class 
planned for the 
studyAge class 
[31]&Weight (kg)
N/ Mean / SE / 
gender [31]ADE Estimated 
SD (BWp)Estimated SD 
(log BWp)Estimated SD 
(log CL/F)
Birth to <1 month Birth -2 
months82 / 5.0 / 0.11 / F 1.2 1.00 0.199 0.239
1 to <3 months Birth -2 
months82 / 5.0 / 0.11 / F 1.2 1.00 0.199 0.239
3 to <6 months 3-5 months 111 / 7.1 / 0.11 / M 1 1.16 0.163 0.163
6 to <12 months 6-8 months
9-11 months103 / 8.7 / 0.13 / M
108 / 9.6 / 0.15 / M *1
11.32
1.56ND
0.162ND
0.162
1 to <2 y ears 1 year 297 / 10.9 / 0.10 / F 1 1.72 0.158 0.158
2 to <5 years 3 years 191 / 15.7 / 0.24 / F 0.9 3.32 0.211 0.190
5 to <12 y ears 9 years 191 / 36.6  / 1.17 / M 0.75 16.2 0.442 0.331
12 <18 years 17 years 188 / 77.4 / 2.41 / M 0.75 33.0 0.427 0.320
&only data related to the age period actually used for the sample size calculations are reported in this table. 
* given that mean values were very similar, data from the class with the larger SD of weights was used 
ADE = age -dependent exponent; BWp= body weight of children; CL/F= systemic clearance; F= Female; M = Male; 
ND= Not Done; SD = Standard Deviation
Sample size was then computed by the R program described in Wang et al 2012 [32] for 
each age class.
The resulted sample size for each treatment group, and the relevant power are provided in 
the table below:
Age class for the study N estimated / dose Power
Birth to < 1 month 6 0.891
1 to <3 months 6 0.891
3 to <6 months 4 0.832
6 to <12 months. 4 0.836
1 to <2 y ears 4 0.854
2 to <5 y ears 5 0.913
5 to <12 y ears 8 0.830
12 to <18 years 8 0.865
In order to facilitate the management of the study, the calculated sample size in the age 
class 2 to < 5 years will be rounded up to 6 patients. 
8.2 Definition of Study Populations for Analysis
The fo llowing analysis populat ions are defined:
Page 286 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 78of 98
CONFIDENTIAL
The Full Analysis Set(FAS) includes all patients rando mized or to whom a study  drug 
was assigned and who received a HEC or MEC regimen and the ent ire planned vo lume o f 
netupi tant and palonosetron. Following the intent-to-treat principle, patients will be 
assigned to the treatment group according to the treatm ent assigned/rando mized. FAS 
will be used for demography , other baseline characteri stics and efficacy analyses.
The PK population includes all patients who received the entire planned volume of 
netupi tant and/or the entireplanned volume of palonosetron and who have at least one 
measurable concentration of netupi tant and/or palonosetron. PK popul ation will be used 
for all PK analyses. 
The Safety popul ation includes all patients who received at least part of the planned 
volume of  netupi tant or at l east part of the planned vol ume of pal onosetron. Pati ents will 
be assigned to treatm ent groups according to the actual  treatm ent received. Safet y 
popul ation will be used for demography, other baseline characteri stics and for all safety 
analyses.
8.3 Statistical Analysis
General Considerations
General descri ptive statist ics for numeric variables will include n (number of observed 
values), mean, standard deviat ion (SD), median, minimum and maximum values. For 
categori cal variables, the nu mber and percentage of patients will be presented.
8.3.1 Missing Data
Due to the descriptive nature of the analysis, no procedure for handling missing data will 
be applied to pharmacokinet ic or safet y data.
For the efficacy analysis, any patients who do not provide data about occurrence of 
emetic episode and rescue medication intake after chemotherapy administrati on (which 
are needed to assess CR) will be considered as treatm ent failures in the relevant phase
with missing information. 
The same approach will be also applied to each component of CR, i.e. emet ic episodes 
and rescue medicat ion intake.
8.3.2 Covariates, Interactions and Subgroups
There are some factors expected to influence the efficacy endpo ints, i.e.,age class, 
emetogeni city of chem otherapy  and schedule of chemotherapy. These factors will be 
taken into consideration for rando mizat ion. Efficacy endpo ints will be presented by 
strata. 
8.3.3 Analysis of Demographics and Baseline Variables
Dem ographics and baseline characteri stic will be summari zed by treatm ent group by 
means of descript ive statist ics, in addition to be listed. Descriptive statistics will be 
presented overall and by strata.
Page 287 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 79of 98
CONFIDENTIAL
8.3.4 Pharmacokinetic Analysis
Exploratory  PK analyses will be applied to evaluate in the pediatri c popul ation the 
disposi tion characteristics of netupi tant, its metabolites and palonosetron observed in 
adult patients. The initial popul ation PK model (base model) will be devel oped by 
comparing structural  models and random error mode ls based on parameters such as the 
objective funct ion values, the log-likelihood values, the Akaike’s and the Bayesian’s 
Inform ation Criteria (AIC and BIC), the residual  errors, the rando m distribut ion in 
condi tional weighted residual plots, the graphical correl ation between the observed 
versus predicted concentration values.
The final popul ation PK model will include possible additional fixed effects represented 
by relevant covari ates that will prove to correlate with one or more popul ation PK 
param eters and contribute to significant ly explain and minimize the inter-subject 
variabilit y. 
The final model will be qualified via a visual predictive check.
Inter -subject / inter-occasi on variabilit y (level 1  random -effect) and observat ion-level 
rando m error (leve l 2 rando m effect) will  also be m odeled.
Individual model-predi cted PK parameter values will be estimated from the final 
popul ation pharmacokinet ic models, based on mean popul ation param eter values (TVs) 
and on the individual random  effect (ηi). Individual plasma -concentrati on-time curves 
will be simulated from final model parameters, and secondary  parameters such as Cmax, 
tmax, AUC and t 1/2estimated by non -compartm ental methods.
Mean and coefficient of variation (CV) of the pharmacokinet ic parameters will be 
calculated from  the individual predict ions.
The effect of continuous and categori cal covariates on the PK param eter variabilit y will 
be evaluated by step-wise forward addit ion and backward eliminat ion procedures. 
Continuous covari ates will include at least age, BW, albumin, total bilirubin, creat inine,
ALT, AST, ALP. Categorical covariates will include at least gender, chemotherapy 
schedule, HEC/MEC, rescue medication (yes/no), concomitant medicat ions.
Adult data fro m previous populat ion PK study  NETU -10-02 [26]after oral administration 
of the netupi tant-palonosetron fixed combinat ion will be used as prior informat ion and 
included in the analysi s. 
8.3.5 Efficacy Analyses
All resul ts will be interpreted in a descriptive manner, since the study  is not powered to 
compare the treatm ent groups for the efficacy assessments.
For each phase (delayed, acute, and overall), numbers and percentages (including 95%
CI) of patients with CR, with no emetic episodes and no rescue medicat ion will be 
summarized by treatm ent. The difference in response rate between the groups and 
relevant 95% CI will be provided as well.
Efficacy analysis will be presented for the overall popul ation and by strata.
Page 288 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 80of 98
CONFIDENTIAL
8.3.6 Pharmacokinetic/Pharmacodynamic Analysis
PK/PD relationships between predicted individual exposure metrics (Cmaxand AUC) of 
netupi tant versus efficacy (CR delayed phase) will be invest igated via graphical 
exploratory analyses. In addition, a logistic regressi on analysis will be used to link the 
exposure metrics (C max, AUC) to categorical response (CR delayed phase).
The dose-exposure relationship and the PK/PD correl ation (exposure -response 
relationship) for netupi tant in pediatric  cancer patients will be com pared to that observed 
in adult cancer patients in order to support the dose select ion for netupitant in the 
pediatric populati on. Similar exposures in adult and pediatric patients are assumed to 
produce similar efficacy .
8.3.7 Safe ty Analyses
All AEs will be listed by SOC, described and summarized by frequency  tables. 
Summaries will be made by treatm ent arm with respect to the percentage of patients 
having at least one occurrence of that event during the study  and the total number of 
events.
For safet y analysis, the laboratory  data will be analyzed and described as foll ows: list ings 
(including flag for values outsi de the norm al range), coun t (number and percentage) of 
value below, within and above norm al range, descript ive statistics for change from 
baseline values. Shift tables with respect to normal range (Low/Norm al/High) will be 
presented. ECG data will be summarized highlight ing differences from baseline for 
quant itative variables and frequencies of treatm ent emergent abnormalit ies. Vital signs 
will be summarized using descri ptive statist ics for observed values and change from 
baseline, in addit ion to being listed. 
Safety analysis will be presented for the overall safety  populati on and by  strata.
8.4 Interim Analysis
No interim analysis is planned for this study .
Page 289 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 81of 98
CONFIDENTIAL
9DATA SAFETY MONITORI NG BOARD
A Data Safety Moni toring Board (DSMB) will be convened for the evaluat ion of safety 
data during the study . The DSMB will not include employees of the Sponsor. 
Com position, rol e and responsibili ties of  the DSMB will be given in a separate docum ent 
named DSMB charter. The purpose of the DSMB is to perform a qualitat ive safet y 
assessment. Study  data will be provi ded to the DSMB, as foreseen by the study  design 
and at periodical intervals. Any additional information will be prom ptly made available 
by the Sponsor upon request of DSMB members.
The DSMB will have periodical  face-to-face and/or telephone meet ings, as appropri ate 
and as foreseen by the study  design, and a set of minutes will be issued aftereach 
meet ing. A charter for the DSMB will be completed before patients enrollment begins.
Page 290 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 82of 98
CONFIDENTIAL
10ETHICAL AND REGULATO RY CONSIDERATIONS
10.1 Ethical Considerations
The study will be performed in accordance with the principles contained in the 
Declaration of Helsinki [33] as amended by the World Medical Associ ation in Fortal eza 
in 2013, and the ICH GCP guidelines as well as all l ocal laws and regulat ions of the USA 
and other coun tries where the study  is conducted, as applicable.
10.1.1 Laws and Regulations
This clinical study  will be conducted in compliance with all internat ional laws and 
regul ations and national laws and regul ations of the USA and other countries wherethe 
trial is perform ed, as applicable, as well as any  applicable guidelines. 
10.1.2 Patient’s In formation Sheet, Informed Consent Form and Assent 
Form 
Before starting any study -specific evaluat ions or procedures, parent(s)/legal guardi an(s) 
of all patients invited to participate in the study and patients of appropri ate age and 
intellectual maturit y as defined by local laws and regul ations must be given written and 
verbal information about the aims, methods, anti cipated benefi ts and potenti al hazards of 
the study . Furtherm ore, the pati ents and thei r parent(s)/legal guardian(s) must be notified 
that participat ion is voluntary, and that the patient is free to withdraw from the study  at 
any t ime wi thout any disadvantages for the pati ent’s subsequent care. The parent(s)/legal 
guardi an(s) is/are also free to wi thdraw their child from  the study  at any time w ithout any 
disadvantages for the child’s subsequent care. 
In addition, parent(s)/l egal guardi an(s) will be given the Information for Parents and 
Inform ed Consent Form  in native language expressed in clear, concise and lay language 
for review and considera tion. As requi red by local laws and regulat ions, all patients of 
appropriate age and intellectual  maturity will be given the Children’s Informati on Sheet 
and Assent Form explaining the study  in age -appropriate term s.
Inform ation for Parents and Informed Consent Form  as well as the Children’s 
Inform ation Sheet and Assent Form  will tell potent ial patients and their parent(s)/l egal 
guardi an(s) about the nature of the drugs, its efficacy and safet y profile, the route of 
administration, and the available clinica l experiences in humans. It will also outline the 
steps of the protocol as they will apply to the individual including the number of visits, 
the number of procedures and ty pes of assessments/measurements to be performed so that 
the individual has a clear picture of the risks, inconveniences and benefits that may 
accrue.
The patients and their parent(s)/l egal guardian(s) must also know that patient’s personal 
medical records may be reviewed in strict confidence by the Sponsor’s staff or 
representatives and by Regulatory  A uthori ties and Independent Ethics 
Committees(IEC)/Institutional Review Board (IRB) and that personal information about 
Page 291 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 83of 98
CONFIDENTIAL
patients will be held on a confidential database. Condi tions for ensuring the anonymit y of 
data and the securit y and confident iality of the database should be explained.
Both the Informed Consent Form  and the assent form must be previ ously approved by 
relevant IEC(s)/IRB and may further be updated as new important informat ion becomes 
available that may affect pati ent’s or pare nt(s)/legal guardian(s) willingness to parti cipate 
or continue in the trial.
Written Inform ed Consent Form  signed by the parent(s)/legal guardian(s) must be 
obtained pri or to enrollment of all pediatri c pati ents and the signed assent form  should be 
obtaine d from all patients of  appropriate age and intellectual maturit y in com pliance wi th 
local laws and regulat ions.
Two copies of the Informed Consent Form and Assent Form  shall be signed. The 
Invest igator shall provide one signed copy  of the Informed Consent Form  to the 
parent(s)/legal guardian(s) and one copy  of the assent form to the child (if applicable), 
and will keep the second copy  of the ori ginal  signed f orms in the Invest igator’s study file.
10.1.3 Protocol Amendments
Changes to the protocol may only be made by means of a wri tten amendment, which has 
to be approved and signed by the authori zed individuals of the Sponsor and by the 
Invest igator. The study  code, the ti tle of the study , the progressive number and the date of 
the amendment must be recorded on the first page of the docum ent. Exhaust ive 
justificat ions that motivate the amendment to the protocol  should clearly  be addressed in 
the docum ent. All  protocol  amendments must be submitted to the EC/IRB for revi ew and 
approval  (as well as to Com petent Authori ties, where applicable for authori zation) unless 
it covers administrative issues only. In this case, the EC/IRB and Competent Authori ties 
will be notified o f the am endment for informat ion purposes only , as applicable .
10.1.4 Protocol Deviations
The Invest igator has to conduct the study  in accordance with the approved current 
protocol  and will not be allowed to make any changes with the only excepti on when 
immediate changes are necessary to protect the safety , rights, and welfare of the patient.
In order to obtain interpretabl e resul ts, neither the Invest igator nor the Sponsor/CROs 
will alter the study  condi tions agreed upon and set out in this protocol. 
In the event that an isolated, unforeseen instance resul ting in a protocol  deviati on occurs, 
the Invest igator i s to document this deviati on and notify it to th e clinical CRO as soon as 
possible, in writing. In no instance shoul d this increase the patient’s risk or affect the 
validit y of the study  data.
10.1.5 Data Collection 
Electronic Case Report Form s (eCRFs) will be used for recording patient’s study  data 
using a validated web-based Electroni c Data Capture (EDC) system . It is the 
responsibilit y of the Invest igator to ensure that the eCRFs are properly and completely 
filled in. The eCRFs must be completed for all patients who have been included in the 
Page 292 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 84of 98
CONFIDENTIAL
study . A screening log will be completed for screening failures. Data of these patients 
will be handled separately fro m the data of patients included in the study .
Each authori zed site personnel will be assigned a login and password to enter the EDC 
system via a secure network . Each login uniquely ident ifies the user and appropri ate 
permissions will be set-up according to the user role. The access to the system will be 
granted once the user’s training will be co mpleted and doc umented. 
Data Cl arificati on Form s (DCFs) will be used to validate/cl arify data entered on an eCRF 
page. Some DCFs will be generated automatically  by the system  when the user saves data 
that does not meet the cri teria pre -defined for the data field. In addition, other DCFs will 
be created manually .
Discrepancies raised will be reviewed online to determine the corrective action needed. 
Changes will be made direct ly by authori zed si te staff. The EDC system’s audit trail will 
keep track of  any informat ion entered, modified and deleted. The audit trail  will include, 
as a minimum, what was entered/changed/modified, who made the act ion and when the 
action was made. Any answered DCF will be reviewed and closed by authorized users. 
The Investigator will electronical ly sign the eCRF to validate the content.
Patient’s source docum entati on (i.e., hospi tal charts) will be maintained at the 
clinic/hospital. Source data to be recorded di rectly on to the eCRFs will be commu nicated 
in advance. In cases where source docum ents are not eCRFs, the informat ion on the 
eCRFs must match the source docum ents. Source data verification will be regularly 
perform ed by  the blinded study  monitor.
10.1.6 Monitoring and Quality Assurance
The study  will be monitored by  CRO’s adequately qualified and trained clinical  monitors 
on a regular basis throughout the study  period to ensure the proper conduct of the clinical 
trial. The purposes of clinical  trial monitoring are to verify that the rights and well-being 
of study patients are protected, that the reported trial data are accurate, complete and 
verifiable against the source documents, and that the study  is conducted in accordance 
with the current protocol , GCP gui deline and applicable regulatory  requirements. During 
the monitoring visits, monitors will verify thefollowing including but not limited to: 
patient/parental  Inform ed Consent Form /Assent Form , patient’s eligibilit y, safety data 
and reporting, qualit y of source docum ents and eCRF data against patient’s medical 
records. If inconsistencies are identified, the corresponding correcti ons to th e eCRF data 
will have to be made by the Investi gator. Monitors will also check patient compliance, 
accrual, drug handling, including dispensing procedures and accountabilit y logs, 
delegation of responsibilit ies within the Investi gator’s team , relevant communicat ions 
with family doctors, if any, ancillary equipment and facilit ies, including refrigerators and 
freezers, local labs, etc. The Investi gator and other site staff involved in the study  must 
allocate enough time to the m onitor at these visits.
Upon request by  the Sponsor, or foll owing the CRO’s audi t plan, on -site study  audi ts will 
be conducted in order to ensure the study is in compliance with GCP, applicable 
regul atory  requirements, and the study  protocol .The auditing activities may also be 
conducted after study  com pletion.
Page 293 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 85of 98
CONFIDENTIAL
In addition, Regulatory  Authori ties may wish to conduct on-site inspect ions (during the 
study  or after its completion). If a  Regulatory  Authori ty notifies the Invest igator of an 
inspect ion or visits the site unannounced for purposes of conducting an inspect ion, the 
Invest igator must inform the study  Sponsor and CRO immediately. The Invest igator will 
make all efforts to facili tate the conduct of  the audi ts and inspections giving access to all 
necessary  facilit ies, data and documents.
10.1.7 Study Documentation and Records Retention
The medical (hospital) files of trial patients shoul d be retained in accordance with 
national legislat ion (and in accordance wit h the m aximum  period of  time permitted by the 
hospi tal (or i nstitution/private practice).
The Sponsor should ensure that it is specified in the protocol  or other written agreement 
that the Invest igator(s)/inst itution(s) will permit trial-related monitoring, audits, IRB/EC 
review, and regulatory inspect ion(s), providing direct access to source data/documents.
All the essent ial study  docum ents [27]shoul d be retained at the sites until when the 
Sponsor informs the Investigators/institutions in writing the date when the trial related 
records are no l onger needed and in any case inaccordance wi th FDA regulati on 21 CFR 
312.62(b) and (c) and ICH- GCP guidelines. Shoul d the Invest igator wish to assign the 
study  documentati on to another party or move to another location, the Sponsor should 
prom ptly be notified.
10.1.8 Confidentiality
The Sponsor and the CRO must ensure that the Invest igator keeps secret from third 
parties any confident ial inform ation discl osed or provi ded by the Sponsor and regarding 
the Sponsor and its study -related products. The Invest igator agrees to use such 
inform ation only to accomplish the present study tasks and not to use it for any other 
purposes without the prior written consent by the Sponsor .Prior to the study  start-up, 
each Invest igator as well as each subcontractor to be involved in the study shoul d sign a 
confident iality agreement wi th the CRO acting for and on behalf of the Sponsor .
10.1.9 Publication Policy
As a general  rule, the Sponsor and the Investi gator(s) agree that no publications 
present ing or discussing data and/or resul ts from clinical trials sponsored by Helsinn 
Healthcare SA will take place until the participating center(s) has/have completed the 
study , the data have been interprete d, and the final report has been issued. As a rule, the 
Sponsor is free to use the data collected in the sponsored study for the drug registrati on, 
world-wide scient ific product documentation, and for publicat ion. In general , the Sponsor 
has no object ions if the Invest igator publishes the resul ts of the study  obtained by the 
Invest igator/Inst itution sponsored by Helsinn Healthcare SA; however, the Investi gator i s 
requested to provide the Sponsor with a  c opy of the manuscript for review before 
submitt ing it to the publisher with a cover letter informing the Sponsor about the 
intention to publish the study  resul ts. Such a procedure is necessary to prevent prem ature 
disclosure of trade secrets or otherwi se patent -protected material and is not intended as a 
Page 294 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 86of 98
CONFIDENTIAL
restrictive measure concerning the study results or the opinions of the Invest igators. After 
the review of the manuscript by the Sponsor, the Invest igator will be provi ded with the 
Sponsor’s comments, if any, and the opinio n of the Sponsor regarding study  results 
publicat ion. The Investi gator shall however consider the Sponsor’s comments and 
proposed revisio ns. If requested by the Sponsor, the Invest igator shall delay  the 
presentation or publicat ion of the study  data in order to all ow the Sponsor sufficient tim e 
to obtain Intellectual  Property  Protecti on. The Sponsor is entitled to incl ude as authors of 
the publicat ion all Sponsor’s personnel who have contributed substant ially to the 
theoreti cal or experimental activities and also to make a decisio n on the order in which 
the authors’ names will be given. Costs for publicat ion must be regul ated by written 
agreem ent between the parties. For multicenter studi es, the Invest igators who will be 
quoted as authors of the publicat ion(s) shoul d be agreed upon with the Spon sor. If 
publicat ion of the resul ts of the study , either in part or in full, is prepared by the Sponsor, 
the Invest igator(s) will be asked in writing if he/she/they agree(s) to be listed as one of 
the authors of the publicat ion. Answers shoul d be sent in writing to the Sponsor within a 
reasonable time limit (30 day s).
10.1.10 Insurance
The Sponsor will obtain liabili ty coverage com pliant wi th the regulati ons of each country 
involved in the study . This insurance will cover health impairments resul ting from drugs 
and/or substances/invest igational products administered in the course of this study  for 
which the pati ent (and/or pati ent’s parent or guardian) has given his/her wri tten Inf ormed 
Consent/Assent. This insurance also covers health impairments resul ting from study 
procedures.
Page 295 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 87of 98
CONFIDENTIAL
11REFERENCES
1 Griffin AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM, Tattersall 
MH. On the receiving end. V: Pat ient percepti ons of the side effects of cancer 
chemotherapy in 1993. Ann Onco l 1996; 7(2): 189 -95.
2 Jordan K, Roila F, Molassiotis A, Maranzano E, Clark-Snow RA, Feyer P. 
Antiemetics in children receiving chem otherapy . MASCC/ESMO guideline update 
2009. Support Care Cancer 2011; 19 Suppl 1: S37-42.
3 Laszlo J, Lucas VS, Jr. Emesis as a critical problem in chem otherapy. N Engl J 
Med 1981; 305(16): 948- 9.
4 Basch E. The missing voice of patients in drug-safet y reporting. N Engl J Med 
2010; 362(10): 865- 9.
5 Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, Daniele B, 
De Pouvourville G, Rubenstein EB, Daugaard G. Incidence of chemotherapy-
induced nausea and emesis after modern antiemetics. Cancer 2004; 100(10): 2261 -
8.
6 Osoba D, Zee B, Warr D, Kaizer L, Latreille J, Pater J. Qualit y of life studi es in 
chemotherapy -induced emesis. Onco logy 1996; 53 Suppl  1: 92 -5.
7 Lin SJ, Hato um HT, Buchner D, Cox D, Balu S. Impact of 5-HT3 receptor 
antagonists on chem otherapy -induced nausea and vomiting: a retrospective cohort 
study . BMC Healt h Serv Res 2012; 12: 215.
8 Jordan K, Sippel C, Schm oll HJ. Guidelines for antiemet ic treatm ent of 
chemo therapy -induced nausea and vomiting: past, present, and future 
recommendat ions. Onco logist 2007; 12(9): 1143 -50.
9 Guideline update for MASCC and ESMO in the prevent ion of chemotherapy- and 
radiotherapy -induced nausea and vomiting: resul ts of the Perugi a consensus 
conference. Annals of Onco logy 2 010; 21(Suppl ement 5):232 -243. 
Updated in Jan 2013: http://www.mascc.org/assets/Guidelines -
Tool s/mascc_ant iemetic_english_2014.pdf.
10 Dupui s LL, Boodhan S, Holdsworth M, Robinson PD, Hain R, Portwine C, 
O'Shaughnessy E, Sung L; Pediatri c Onco logy Group of Ontari o. Gui deline for the 
prevent ion of acute nausea and vomiting due to antineoplast ic medicat ion in 
pediatric cancer patients. Pediatr Blood Cancer 2013; 60(7): 1073 -82.
11 Kang HJ, Lo ftus S, Taylor A, DiCrist ina C, Green S, Zwaan CM. Aprepitant for the 
prevent ion of chemotherapy- induced nausea and vomiting in children: a 
rando mised, double -blind, phase 3 trial. Lancet Oncol 2015; 16(4): 385 -94.
12 Rojas C, Raje M, Tsukam oto T, Sl usher BS. Molecular mechanisms of 5-HT3and 
NK1receptor antagonists in prevent ion of emesis. Eur J Pharmaco l2014; 722:26 -
37.
13 Invest igator’s Drug Brochure Palonosetron, Revised Edit ion: Apr 2018.
Page 296 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 88of 98
CONFIDENTIAL
14 Study  Report PALO -99-07. Double-Blind Pediatri c Study  to Assess the Safet y, 
Pharmacokinet ics and Efficacy of Single IV Doses of Palonosetron, 3.0 μg/kg or 
10.0 μg/kg, in the Prevent ion of Chemotherapy- Induced Nausea and Vomiting. 06 
Feb 2006.
15 Study  Report PALO -10-20. A Multicenter, Randomized, Doubl e-Blind, Parallel 
Group Study to Evaluate the Efficacy and Safety  of Two Different Doses of 
Palonosetron Com pared to Ondansetron in the Prevent ion of CINV in Pediatric 
Patients Undergoing Single and Repeated Cy cles of MEC or HEC. 24 Oct 2013.
16 Invest igator’s Brochure Oral Netupi tant/Pal onosetron Fixed -dose Combina tion, 
Revised Edit ion: Dec 2018 .
17 NCCN Clinical Pract ice Guidelines in Onco logy (NCCN Guidelines). Antiemesis 
Versi on 1, 2014, http://www.nccn.org/.
18 Study  Report PALO -07-29. A Multicenter, Double-blind, Rando mized, Parallel 
Group, Stratified Study  to Assess the Safet y and Efficacy of Single IV Doses of 
Palonosetron to Prevent Postoperative Nausea and Vomit ing in Pediatri c Patients. 
13 Jul  2009. 
19 Study  Report PALO -10-14. A Multicenter, Doubl e-blind, Double- dummy, 
Randomized, Parallel Group, Stratified Study  to Evaluate the Efficacy  and Safet y 
of a Single IV Dose of Pal onosetron Com pared to a Single IV Dose of Ondansetron 
to Prevent Postoperative Nausea and Vomit ing in Pedi atric Pati ents. 05 Sep 2013.
20 Study  Report NETU -07-07. A Rando mized, Double- Blind, Paralle l Group, Dose-
Ranging, Multicenter Study  Assessing the Effect of Different Doses of Netupi tant 
or Placebo Administered with Palonosetron and Dexamethasone on the Prevent ion 
of Highly Emetogeni c Chem otherapy -Induced Nausea and Vomiting in Cancer 
Patient. 16Feb 2010.
21 Study  Report NETU -08-18. A phase III multic enter, randomized, doubl e-blind, 
doubl e-dummy, act ive-controlled, parallel group study  of the efficacy and safety of 
oral netupi tant administered in combination with palonosetron and dexamethasone 
compared to oral pal onosetron and dexamethasone for the prevent ion of nausea and 
vomiting in cancer pat ients receiving m oderately emetogeni c chem otherapy . 12 Jun 
2013.
22 Study  Report NETU -10-29. A phase III, multicenter, randomized, doubl e-blind, 
unbalanced (3:1) active control study  to assess the safety  and describe the efficac y 
of netupi tant and palonosetron for the prevent ion of chemotherapy -induced nausea 
and vo miting in repeated chemotherapy cycles. 05 Jun 2013.
23 Natal e JJ, Spinelli T, Calcagnile S, Lanzarotti C, Rossi  G, Cox D, Kashef K. Drug -
drug interacti on profile of components of a fixed combinat ion of netupi tant and 
palonosetron: Review of clinical data. J Oncol Pharm Pract. 2016; 22(3):485-495.
24 Mahm ood I. D osing in children: a critical review of the pharmacokinet ic allometry 
scaling and modeling approaches in paediat ric drug development and clinical 
settings. Clin Pharmacokinet 2014; 53:327- 346. 
Page 297 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 89of 98
CONFIDENTIAL
25 Centers for Disease and Control  Prevent ion. National Centers for Health Statistics. 
www.cdc.gov/growthcharts.
26 Study  Report NETU -10-02. Determinat ion of netupi tant and its metabolites M1-
M3, and of palonosetron concentrations in human plasma. 23 May  2013. 
27 International Conference on Harm onizat ion of Technical  Requirements for 
Registration of Pharmaceut icals for Human Use. ICH –Efficacy Topi c 6(R1): 
Guideline for Good Clinical Practice, Step 4, 10 Jun 1996 and Step 5, July 2002.
28 Commo n Termino logy Criteria for Adverse Events (CTCAE) (Termino logy 
Criteria for Adverse Events (CTCAE, Versi on 4.0, published: May 28, 2009 
[v4.03: Jun 14, 2010]). 
29 International Conference on Harm onization of Technical  Requirements for 
Registration of Pharmaceut icals for Hum an Use. ICH –Efficacy Topic E2A: 
Clinical Safet y Data Management: Definit ion and Standards for Expedi te reporting, 
June 1995.
30 International Conference on Harm onizat ion of Technical Requi rements for 
Registration of Pharmaceut icals for Human Use. ICH –Efficacy Topi c 9: Guidance 
on Statistical Principles for Clinical Trials, 5 Feb 1998.
31 Fryar CD, Gu Q, Ogden CL. Anthropometric reference data for children and adult s: 
United States, 2007–2010. National Center for Health Statist ics. Vital Health Stat 
11(252). 2012. 
32 Wang Y, Jadhav PR, Lala M, Gobburu JV. Clarificat ion on precisio n criteria to 
derive sample size when designing pediatric pharmacokinet ic studies. J Clin 
Pharmaco l 2012; 52:16 01-1606.
33 WMA Declarat ion of Helsinki -Ethical Principles for Medi cal Research Involving 
Hum an Subjects. 64th WMA General Assembly, Brazil, Fortaleza, Oct 2013.
34 Oken MM, Creech RH, Torm ey DC, Horton J, Davis TE, McFadden ET, Carbone 
PP. Toxicity and Respon se Criteria of The Eastern Cooperative Onco logy Group. 
Am J Clin Onco l 1982;5:649-655.
35 POGO Guideline for Classificat ion of the Acute Emetogeni c Potenti al of 
Antineoplastic Medicat ion in Pediatri c Cancer Patients. 
http://www.pogo.ca/_media/File/guidelines/ POGO%20Em etogeni city%20Classific
ation%20Guideline%20Final -rev-%20250111.pdf.
36 Schwartz GJ, Work DF. Measurement and Estimation of GFR in Children and 
Adolescents. Clin J Am Soc Nephro l 2009; 4:1832–1843.
37US FDA Deferral  Extensi onletter dated 15 Jan 2019 .
38Ethical considerat ions for clinical trials on medi cinal products conducted with 
minors Recommendations of the expert group on clinical trials for the 
implementation of Regulat ion (EU) No 536/2014 on clinical trials on medicinal 
products for human use Revis ion 1 18 September 2017 .
Page 298 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 90of 98
CONFIDENTIAL
(https://ec.europa.eu/health/sites/healt h/files/files/eudralex/vo l-
10/2017_09_18_ethical_consid_ct_wi th_minors.pdf )
Page 299 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2019 Clinical Study  Protocol
Page 91of 98
CONFIDENTIAL
12APPENDICES
Appendix 1: Treatment scheme
Appendix 2:Emetogenic potential of IV and oral ant ineoplastic agents
Appendix 3:Eastern Cooperative Oncology  Group Perfor mance Status (ECOG PS) 
Appendix 4:List of CYP3A4 Inducers, strong and moderate Inhibitors, and Substrates
Appendix 5:Schwartz equation for determining estimated glo merular filtrat ion rate 
(eGFR)
Page 300 of 323
NEPA -15-31 
Final (v. 5.0)/11 Feb 2018 Clinical Study  Protocol
Page 92of 98
CONFIDENTIAL
Appendix 1: Treatment Scheme
Enrollment 
Age classes 1 -
<18years
All randomized to NETU 
1.33mg/kg or 4mg/kg
Planned patient numbers 
by age class: 
•12 -<18years    N=16
•5 -<12years   N=16
•2 -<5years   N=12
•1 -<2years   N=8Enrollment    N=3
Age class 6 -<12months
Open treatment with 
NETU 1.33mg/kgStart
YES YESEnrollment    N=3
Age class 6 -<12months
Open treatment with 
NETU 4mg/kgEnrollment    N=2
Age class 6 -<12months
All randomized to NETU 
1.33mg/kg or 4mg/kgYES
Enrollment    N=3
Age class 3 -<6months
Open treatment with 
NETU 1.33mg/kgEnrollment    N=3
Age class 3 -<6 months
Open treatment with 
NETU 4mg/kgEnrollment    N=2
Age class 3 -<6months
All randomized to NETU 
1.33mg/kg or 4mg/kgNOSTOP
DSMB 
approved?
STOP NO
DSMB 
approved?DSMB 
approved?NOSTOP
YES DSMB 
approved?STOP NO
YES
Enrollment    N=3
Age class 1 -<3months
Open treatment with 
NETU 0.8mg/kgEnrollment    N=3
Age class 1 -<3 months
Open treatment with 
NETU 2.4mg/kgEnrollment    N=6
Age class 1 -<3 months
All randomized to NETU 
0.8mg/kg or 2.4mg/kgSTOP NO
DSMB 
approved?YES DSMB 
approved?STOP NO
YES
Enrollment    N=3
Age class <1month
Open treatment with 
NETU 0.8mg/kgEnrollment    N=3
Age class  <1 month
Open treatment with 
NETU 2.4mg/kgEnrollment    N=6
Age class <1month
All randomized to NETU 
0.8mg/kg or 2.4mg/kgSTOP NO
DSMB 
approved?YES DSMB 
approved?STOP NO
YES
Page 301 of 323
NEPA -15-31 
Final (v. 5.0)/ 11 Feb 2019 Clinical Study  Protocol
Appendix 2: POGO Guideline for Classification of the Acute 
Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer 
Patients [35]*
Emetogenicity IV Agents Oral Agents
High
(>90% frequency of 
emesis in absence of 
prophylaxis)Altretamine 
Carboplatin 
Carmustine >250 mg/m2
Cisplatin 
Cyclophosphamide ≥1 g/m2
Cytarabine 3 g/m2/dose 
Dacarbazine
Dactinomycin
Mechlorethamine
Methotrexate >12 g/m2
Streptozocin
Thiotepa ≥300 mg/m2Procarbazine 
Moderate 
(30–90% frequency 
of emesis in absence 
of prophylaxis)Aldesleukin >12 to 15 million U/m2
Amifostine >300 mg/m2
Arsenic trioxide
Azacitidine
Bendamustine 
Busulfan
Carmustine ≤ 250 mg/m2
Clofarabine 
Cyclophosphamide <1 g/m2
Cytarabine >200 mg/m2to <3 g/m2
Daunorubicin 
Doxorubicin
Epirubicin 
Idarubicin
Ifosfamide
Intrathecal therapy (methotrexate, 
hydrocortiso ne, and cy tarabine)
Irinotecan
Lomustine
Melphalan >50 mg/m2
Methotrexate ≥ 250 mg/m2to <12 g/m2
Oxaliplatin >75 mg/m2Cyclophosphamide 
Etoposide 
Imatinib 
Temozolomide 
Vinorelbine 
Page 302 of 323
NEPA -15-31 
Final (v. 5.0)/ 11 Feb 2019 Clinical Study  Protocol
Emetogenicity IV Agents Oral Agents
Low 
(10 to <30% 
frequency of emesis 
in absence of 
prophylaxis)Amifostine ≤300 mg/m2
Amsacrine 
Bexarotene
Capecitabine 
Cytarabine ≤ 200 mg/m2
Docetaxel 
Doxorubicin (liposomal) 
Etoposide
5-Fluorouracil
Gemcitabine
Ixabepilone
Methotrexate >50 mg/m2to <250 mg/m2
Mitomycin
Mitoxantrone
Nilotinib
Paclitaxel
Paclitaxel -albumin
Pemetrexed
Teniposide
Thiotepa <300 mg/m2
Topotecan
VorinostatBusulfan 
Fludarabine 
Minimal 
(<10% frequency of 
emesis in absence of 
prophylaxis)Alemtuzumab 
Alpha interferon 
Asparaginase (IM or IV) 
Bevacizumab 
Bleomycin 
Bortezomib 
Cetuximab 
Cladribine (2-ch lorodeoxyadenosine) 
Dasatinib
Decitabine
Denileukin diftitox 
Dexrazoxane 
Erlotinib 
Fludarabine
Gefitinib
Gemtuzumab ozogamicin
LapatinibChlorambucil 
Hydroxyurea 
Melphalan (low-dose) 
Mercaptopurine 
Thioguanine 
Page 303 of 323
NEPA -15-31 
Final (v. 5.0)/ 11 Feb 2019 Clinical Study  Protocol
Emetogenicity IV Agents Oral Agents
Lenalidomide
Methotrexate ≤ 50 mg/m2
Nelarabine
Panitumumab
Pentostatin
Rituximab
Sorafenib
Sunitinib 
Temsirolimus
Thalidomide
Trastuzumab
Valrubicin
Vinblastine
Vincristine
Vindesine
Vinorelbine
*Although not mentioned in this POGO Guideline, Temozolomide given intravenously 
shoul d be considered as moderately  emetogeni c chem otherapy  (MEC).
Page 304 of 323
NEPA -15-31 
Final (v. 5.0)/ 11 Feb 2019 Clinical Study  Protocol
Appendix 3:Eastern Cooperative Oncology Group Performance Status 
(ECOG PS)
Grade ECOG
0Fully active, able to carry  on all pre-disease perform ance without 
restri ction
1Restricted in physically strenuous activity but ambulatory and able to 
carry  out work of a light or sedentary  nature, e.g., light house work, 
office work
2Ambulatory  and capable of all self-care but unable to carry  out any 
work acti vities. Up and about more than 50% of waking hours
3Capable of only limited self-care, confined to bed or chair more than 
50% of waking hours
4Com pletely disabled. Cannot carry  on any self-care. Totally confined to 
bed or chair
5 Dead
As published in Am J Clin Onco l: 
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. 
Toxicit y And Response Criteria Of The Eastern Cooperative Onco logy Group; Am  J Clin 
Onco l 5:649 -655; 1982 [34].
Page 305 of 323
NEPA -15-31 
Final (v. 5.0)/ 11 Feb 2019 Clinical Study  Protocol
Appendix 4:CYP3A4 and CYP2D6 Inhibitors, Inducers and Substrates
Strong inhibitors: ≥ 5-fold increase in AUC or > 80% decrease in CL
Moderate inhibitors: ≥ 2 but < 5-fold increase in AUC or 50- 80% decrease in CL
Strong inducers: ≥ 80% decrease in AUC
Moderate Inducers: 50- 80% decrease in AUC
Type Agent
Strong and Moderate Inducers Strong CYP3A4 inducers: carbamazepine, phenytoin, rifampin, St. 
John’s wort
Moderate CYP3A4 inducers: bosentan, efavirenz, etravirine, 
modafinil, nafcillin 
Strong and moderate CYP2D6 inducers: none known
Strong and Moderate Inhibitors Strong CYP3A4 inhibitors: boceprevir, clarithromycin, conivaptan, 
grapefruit juice, indinavir, itracona zole, ketoconazole, 
lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, 
ritonavir, saquinavir, telaprevir, telithromycin, voriconazole 
Moderate CYP3A4 inhibito rs: amprenavir, aprepitant, atazanavir, 
ciprofloxacin, darunavir/ritonavir, diltiazem, erythromy cin, 
fluconazole, fosamprenavir, grapefruit juice, imatinib, verapamil
Strong CYP2D6 inhibitors: bupropion, fluoxetine, paroxetine, 
quinidine
Moderate CYP2D6 inhibitors: cinacalcet, duloxetine, terbinafine
Substrates with narrow 
therapeutic rangeCYP3A4: alfentanil, astemizole, cisapride, cyclosporine, 
dihydroergotamine, ergotamine, fentany l, pimozide, quinidine, 
sirolimus, tacrolimus, terfenadine
CYP2D6: thioridazine
Lists of in vivo inhibitors, inducers and substrates are taken from the following FDA 
website: 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugIn
teracti onsLabeling/ucm093664.ht m
Page 306 of 323
NEPA -15-31 
Final (v. 5.0)/ 11 Feb 2019 Clinical Study  Protocol
Appendix 5:Schwartz equation for determining e stimated glomerular 
filtration rate (eGFR)
eGFR = 0.413 x height (cm)/serum creatinine (mg/dl)
To convert serum  creatinine from µmol/l to mg/dl, the following equat ion shoul d be 
used:
Serum  creatinine (mg/dl) = Serum creat inine (µmol/l) x 0.0113
Schwartz G J and Work DF, 2009 [36]
Page 307 of 323